10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2009

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From                      to                     

Commission File Number: 001-34097

Lorillard, Inc.

(Exact name of registrant as specified in its charter)

Delaware	13-1911176
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

714 Green Valley Road, Greensboro, North Carolina 27408-7018
(Address of principal executive offices) (Zip Code)

(336) 335-7000
(Registrant’s telephone number, including area code)

NOT APPLICABLE
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ       No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes o       No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer þ	Accelerated filer o	Non-accelerated filer o	Smaller reporting company o
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o       No þ

Class	Outstanding at April 29, 2009
Common stock, $0.01 par value	168,169,110 shares

TABLE OF CONTENTS

	Page No.
PART I. FINANCIAL INFORMATION		1
Item 1. Financial Statements		1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		18
Item 3. Quantitative and Qualitative Disclosures about Market Risk		25
Item 4. Controls and Procedures		25
PART II. OTHER INFORMATION		26
Item 1. Legal Proceedings		26
Item 1A. Risk Factors		26
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		28
Item 3. Defaults Upon Senior Securities		28
Item 4. Submissions of Matters to a Vote of Security Holders		28
Item 5. Other Information		28
Item 6. Exhibits		29
SIGNATURES		S-1
EX-10.1
EX-10.2
EX-31.1
EX-31.2
EX-32.1

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

LORILLARD, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED BALANCE SHEETS
(UNAUDITED)

	March 31,			December 31,
	2009			2008
	(In millions)
Assets:
Cash and cash equivalents	$	1,483		$	1,191
Accounts receivables, less allowance of $2 and $2		9			7
Other Receivables		52			55
Inventories		353			255
Deferred income taxes		454			454
Total current assets		2,351			1,962
Plant and equipment		220			218
Prepaid pension assets		37			36
Other investments		15			15
Deferred taxes and other assets		96			90
Total assets	$	2,719		$	2,321
Liabilities and Shareholders’ Equity:
Accounts and drafts payable	$	21		$	30
Accrued liabilities		279			255
Settlement costs		1,217			974
Income taxes		111			14
Total current liabilities		1,628			1,273
Postretirement pension, medical and life insurance benefits		320			317
Other liabilities		102			100
Total liabilities		2,050			1,690
Commitments and Contingent Liabilities
Shareholders’ Equity:
Preferred stock, $0.01 par value, authorized 10 million shares		—			—
Common stock:
Authorized—600 million shares; par value — $0.01 per share
Issued—174 million and 174 million shares
Outstanding—168 million and 174 million shares		2			2
Additional paid-in capital		228			222
Earnings retained in the business		994			965
Accumulated other comprehensive loss		(155	)		(158	)
		1,069			1,031
Treasury shares at cost, 6 million shares in 2008		(400	)		(400	)
Total shareholders’ equity		669			631
Total liabilities and shareholders’ equity	$	2,719		$	2,321

See Notes to Consolidated Condensed Financial Statements

LORILLARD, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(UNAUDITED)

	Three Months Ended
	March 31,
(In millions, except per share data)	2009		2008
Net sales (including excise taxes of $150 and $163, respectively)	$	917	$	921
Cost of sales		532		555
Gross profit		385		366
Selling, general and administrative		91		100
Operating income		294		266
Other income (expense), net		1		9
Income before income taxes		295		275
Income taxes		111		101
Net income	$	184	$	174
Earnings per share:
Basic	$	1.09	$	1.00
Diluted	$	1.09	$	1.00
Number of shares outstanding:
Basic		168.07		173.92
Diluted		168.18		173.92

See Notes to Consolidated Condensed Financial Statements

-2-

LORILLARD, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY
(UNAUDITED)

											Accumu
											lated						Total
	Compre-				Additional			Earnings			Other						Sharehold-
	hensive		Common		Paid-in			Retained in			Compre-			Treasury			ers’
	Income		Stock		Capital			the Business			hensive Loss			Shares			Equity
	(In millions)
Balance January 1, 2008, as previously reported			$	—	$	219		$	882		$	(88	)	$	—		$	1,013
Par value adjustment, Lorillard common stock — 1.7 million to 1 stock split				2		(2	)											—
Balance, January 1, 2008, as adjusted				2		217			882			(88	)		—		$	1,013
Comprehensive income:
Net income	$	174							174									174
Other comprehensive gains, pension liability		1										1						1
Comprehensive income	$	175
Dividends paid									(291	)								(291	)
Share-based compensation						1												1
Balance, March 31, 2008			$	2	$	218		$	765		$	(87	)	$	—		$	898
Balance, January 1, 2009			$	2	$	222		$	965		$	(158	)	$	(400	)	$	631
Comprehensive income:
Net income	$	184							184									184
Other comprehensive gains, pension liability		3										3						3
Comprehensive income	$	187
Dividends paid									(155	)								(155	)
Share-based compensation						6												6
Balance, March 31, 2009			$	2	$	228		$	994		$	(155	)	$	(400	)	$	669

See Notes to Consolidated Condensed Financial Statements

-3-

LORILLARD, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)

	Three Months Ended
	March 31,
	2009			2008
	(In millions)
Cash flows from operating activities:
Net income	$	184		$	174
Adjustments to reconcile net cash provided (used in) by operating activities :
Depreciation and amortization		8			9
Deferred income taxes		—			89
Changes in operating assets and liabilities:
Accounts receivable		—			(2	)
Inventories		(98	)		(36	)
Accounts payable and accrued liabilities		16			14
Settlement costs		243			253
Income taxes		97			4
Other assets		(4	)		(3	)
Postretirement health and life insurance benefits		7			2
Other		—			(5	)
Net cash provided by operating activities		453			499
Cash flows from investing activities:
Purchases of investments		—			(800	)
Proceeds from sales of investments		—			196
Additions to plant and equipment		(10	)		(7	)
Net cash used in investing activities		(10	)		(611	)
Cash flows from financing activities:
Dividends paid		(155	)		(291	)
Excess tax benefits from share-based arrangements		4			—
Net cash used in financing activities		(151	)		(291	)
Change in cash and cash equivalents		292			(403	)
Cash and cash equivalents, beginning of year		1,191			1,210
Cash and cash equivalents, end of period	$	1,483		$	807
Cash paid for income taxes	$	14		$	16

See Notes to Consolidated Condensed Financial Statements

-4-

LORILLARD, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation

          Overview. Lorillard, Inc., through its subsidiaries, is engaged in the manufacture and sale of cigarettes. Its principal products are marketed under the brand names of Newport, Kent, True, Maverick and Old Gold with substantially all of its sales in the United States of America.

          The consolidated condensed financial statements of Lorillard, Inc. (the “Company”), together with its subsidiaries (“Lorillard”), include the accounts of the Company and its subsidiaries after the elimination of intercompany accounts and transactions. The Company manages its operations on the basis of one reportable segment through its principal subsidiary, Lorillard Tobacco Company (“Lorillard Tobacco”).

          The accompanying unaudited consolidated condensed financial statements reflect all adjustments necessary to present fairly the financial position as of March 31, 2009 and December 31, 2008 and the unaudited consolidated condensed statements of income, shareholders’ equity and changes in cash flows for the three months ended March 31, 2009 and 2008.

          Results of operations for the three months for each of the years reported herein are not necessarily indicative of results of operations of the entire year.

          These consolidated condensed financial statements should be read in conjunction with the Consolidated Financial Statements and related Notes to Consolidated Financial Statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission (the “SEC”) on March 2, 2009.

          On May 7, 2008, the Company amended its certificate of incorporation to affect a 1,739,234.29 for 1 stock split of its 100 shares of common stock then outstanding. All common share and per share information has been retroactively adjusted for the periods presented.

          On June 10, 2008, Loews Corporation (“Loews”) distributed 108,478,429 shares of common stock of the Company in exchange for and in redemption of all 108,478,429 outstanding shares of Loews’ Carolina Group stock, as described in the Registration Statement (File No. 333-149051) on Form S-4 filed with the SEC under the Securities act of 1933, as amended (the “Separation”). Pursuant to the terms of the Exchange Offer, described in the Registration Statement, on June 16, 2008, Loews accepted 93,492,857 shares of Loews common stock in exchange for 65,445,000 shares of the Company’s common stock. As a result of such distributions, Loews ceased to own any equity interest in the Company and the Company became an independent publicly held company.

          Prior to the Separation, Lorillard was included in the Loews consolidated federal income tax return, and federal income tax liabilities were included on the balance sheet of Loews. Under the terms of the pre-Separation Tax Allocation Agreement between Lorillard and Loews, the Company made payments to, or was reimbursed by, Loews for the tax effects resulting from its inclusion in Loews’ consolidated federal income tax return. As of March 31, 2009, Loews is obligated to reimburse Lorillard $14 million related to pre-Separation tax benefits and payments, which will be reimbursed by December 2009.

          Recently adopted accounting pronouncements. Lorillard adopted Financial Accounting Standards Board (“FASB”) Statement of Financial Accounting Standards (“SFAS”) No. 157, “Fair Value Measurements,” on January 1, 2008, utilizing the one year deferral that was granted for the implementation of SFAS No. 157 for all nonrecurring fair value measurements of non-financial assets and liabilities. The one year deferral expired on January 1, 2009. SFAS No. 157 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The adoption of SFAS No. 157 did not have a material impact on Lorillard’s financial position or results of operations.

-5-

          In May 2008, the FASB issued SFAS No. 162, “The Hierarchy of Generally Accepted Accounting Principles.” SFAS No. 162 identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles in the United States. SFAS No. 162 is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, “The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles.” The effective date for SFAS No. 162 is November 15, 2008. The adoption of SFAS No. 162 did not have a material impact on Lorillard’s financial position or results of operations.

          In June 2008, the FASB issued FASB Staff Position (“FSP”) Emerging Issues Task Force ((“EITF”) Issue No. 03-6-1, “Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities,” which addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and, therefore, need to be included in the earnings allocation in computing earnings per share. This interpretation is effective for financial statements issued for fiscal years beginning after December 15, 2008 and interim periods within those years. Lorillard adopted this interpretation on January 1, 2009. The adoption of EITF 03-6-1 did not have a material impact on Lorillard’s financial position or results of operations.

          In October 2008, the FASB issued FSP FAS 157-3, “Determining the Fair Value of a Financial Asset When the Market for that Asset is Not Active,” which clarifies the application of SFAS No. 157 (described above) in a market that is not active. The effective date for FSP FAS 157-3 is October 10, 2008. The adoption of FSP FAS 157-3 did not have a material impact on Lorillard’s financial position or results of operations.

          In December 2007, the FASB ratified EITF Issue No. 07-1, “Accounting for Collaborative Arrangements” effective for fiscal years beginning after December 15, 2008. EITF 07-1 defines a collaborative arrangement as an arrangement where the parties are active participants and have exposure to significant risks. Transactions with third parties should be classified in the financial statements in the appropriate category according to EITF Issue No. 99-19, “Reporting Revenue Gross as a Principal versus Net as an Agent.” Payments between the partners of the collaborative agreement should be categorized based on the terms of the agreement, business operations, and authoritative literature. Lorillard adopted this interpretation on January 1, 2009. The adoption of EITF 07-1 did not have a material impact on Lorillard’s financial position or results of operations.

          Accounting pronouncements not yet adopted. In December 2008, the FASB issued FSP FAS 132(R)-1, “Employers’ Disclosures About Postretirement Benefit Plan Assets,” effective for years ending after December 15, 2009 with early application permitted. FSP FAS 132(R)-1 requires disclosure of investment policies and strategies in narrative form. FSP FAS 132(R)-1 also requires employer disclosure on the fair value of plan assets, including (a) the level in the fair value hierarchy, (b) a reconciliation of beginning and ending fair value balances for Level 3 assets, and (c) information on inputs and valuation techniques.

          In April 2009, the FASB issued FSP FAS 107-1 and APB 28-1, “Interim Disclosures about Fair Value of Financial Instruments” which requires interim disclosures on the fair value of financial instruments. The effective date is for interim periods ending after June 15, 2009.

          In April 2009, the FASB issued FSP FAS 157-4, “Determining Whether a Market is not Active and a Transaction is not Distressed,” which utilizes a two step model to determine if the market is inactive and then to determine if the transaction is distressed. The effective date is for interim and annual periods ending after June 15, 2009. Lorillard is evaluating the impact that adopting FSP FAS 157-4 will have on its financial position or results of operations.

          In April 2009, the FASB issued FSP FAS 115-2 and FAS 124-2, “Recognition and Presentation of Other-Than-Temporary Impairments,” which requires that other-than-temporary impairments for debt securities be based on whether the entity intends to sell the security or the entity will more likely than not be required to sell the security before it recovers its cost basis. The effective date is for interim and annual periods ending after June 15, 2009. Lorillard is evaluating the impact that adopting FSP FAS 115-2 and FAS 124-2 will have on its financial position or results of operations.

-6-

2. Inventories

          Inventories are valued at the lower of cost, determined on a last-in, first-out (“LIFO”) basis, or market and consisted of the following:

	March 31,		December 31,
	2009		2008
	(In millions)
Leaf tobacco	$	252	$	208
Manufactured stock		95		42
Material and supplies		6		5
	$	353	$	255

          If the average cost method of accounting was used, inventories would be greater by approximately $163 and $155 million at March 31, 2009 and December 31, 2008, respectively.

3. Plant and Equipment

          Plant and equipment is stated at cost and consisted of the following:

	March 31,			December 31,
	2009			2008
	(In millions)
Land	$	3		$	3
Buildings		87			87
Equipment		541			532
Total		631			622
Accumulated depreciation		(411	)		(404	)
Plant and equipment, net	$	220		$	218

4. Accrued Liabilities

          Accrued liabilities were as follows:

	March 31,		December 31,
	2009		2008
	(In millions)
Legal fees	$	25	$	21
Salaries and other compensation		20		21
Medical and other employee benefit plans		29		27
Consumer rebates		54		62
Sales promotion		23		23
Excise and other taxes		74		56
Other accrued liabilities		54		45
Total	$	279	$	255

-7-

5. Fair Value

          Fair value is the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy is used in selecting inputs, with the highest priority given to Level 1, as these are the most transparent or reliable:

• Level 1 — Quoted prices for identical instruments in active markets.

• Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable directly or indirectly.

• Level 3 — Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

          Lorillard is responsible for the valuation process and as part of this process may use data from outside sources in establishing fair value. Lorillard performs due diligence to understand the inputs used or how the data was calculated or derived, and corroborates the reasonableness of external inputs in the valuation process.

          Assets and liabilities measured at fair value on a recurring basis are summarized below. The valuation of securities that are actively traded or have quoted prices are classified as Level 1. These securities include repurchase agreements and money market funds and were valued as follows at March 31, 2009:

	Level 1		Level 2		Level 3		Total
	(In millions)
Cash	$	1	$	—	$	—	$	1
Repurchase agreements collateralized by treasury securities		155		—		—		155
Treasury money market funds		23		—		—		23
Government money market funds		1,303		—		—		1,303
Prime money market funds		1		—		—		1
Total cash and cash equivalents	$	1,483	$	—	$	—	$	1,483

6. Earnings Per Share

          Basic and diluted earnings per share (“EPS”) were calculated using the following:

	Three Months Ended
	March 31,
	2009		2008
	(In millions)
Net Earnings	$	184	$	174
Weighted Average Shares Outstanding — Basic		168.07		173.92
Stock Options and Stock Appreciation Rights		.11		.00
Weighted Average Shares Outstanding — Diluted		168.18		173.92

          Options to purchase 0.6 million shares of common stock were excluded from the diluted earnings per share calculation because their effect would be anti-dilutive for the quarter ended March 31, 2009.

          Loews distributed its interest in the Company to holders of Loews’ Carolina Group stock and Loews’ common stock in a series of transactions which were completed on June 10, 2008 and June 16, 2008, respectively. The Company had 173,923,429 shares outstanding as of the Separation from Loews. All prior period EPS amounts have been adjusted to reflect the new capital structure of the Company.

-8-

7. Benefit Plans

          Lorillard has defined benefit pension, postretirement benefits, profit sharing and savings plans for eligible employees.

          Net periodic benefit cost components were as follows:

	Three Months Ended
	March 31,
Pension Benefits	2009			2008
	(In millions)
Service cost	$	4		$	4
Interest cost		14			14
Expected return on plan assets		(15	)		(17	)
Amortization of net loss		4			—
Amortization of prior service cost		1			1
Net periodic benefit cost	$	8		$	2

	Three Months Ended
	March 31,
Other Postretirement Benefits	2009		2008
	(In millions)
Service cost	$	1	$	1
Interest cost		3		3
Amortization of net loss		—		—
Net periodic benefit cost	$	4	$	4

8. Legal Proceedings

Legal Proceedings

Tobacco-Related Product Liability Litigation

     As of April 27, 2009, approximately 6,850 product liability cases are pending against cigarette manufacturers in the United States. Lorillard Tobacco is a defendant in approximately 5,900 of these cases. Lorillard, Inc. is a co-defendant in approximately 1,085 cases. Approximately 3,200 of these lawsuits are Engle Progeny Cases, described below, in which the claims of approximately 8,650 individual plaintiffs are asserted.

     The pending product liability cases are composed of the following types of cases:

     Conventional Product Liability Cases. Conventional Product Liability Cases are brought by individuals who allege cancer or other health effects caused by smoking cigarettes, by using smokeless tobacco products, by addiction to tobacco, or by exposure to environmental tobacco smoke. Approximately 155 cases are pending against cigarette manufacturers, including approximately 35 cases against Lorillard Tobacco. Lorillard, Inc. is a co-defendant in eight cases.

     Engle Progeny Cases. Engle Progeny Cases are brought by individuals who purport to be members of the decertified Engle class. These cases are pending in a number of Florida courts. Lorillard Tobacco is a defendant in approximately 3,200 Engle Progeny Cases. Lorillard, Inc. is a defendant in approximately 1,075 cases. Lorillard Tobacco is a party to each of the Engle Progeny Cases in which Lorillard, Inc. is named as a defendant. Many of the cases have been filed on behalf of multiple class members, and approximately 8,650 individual smokers are asserting claims in the pending cases.

-9-

     West Virginia Individual Personal Injury Cases. West Virginia Individual Personal Injury Cases are brought by individuals who allege cancer or other health effects caused by smoking cigarettes, by using smokeless tobacco products, or by addiction to cigarette smoking. The cases are pending in a single West Virginia court and have been consolidated for trial. Lorillard Tobacco is a defendant in approximately 55 of the 730 pending cases that are part of this proceeding. Lorillard, Inc. is not a defendant in any of these cases.

     Flight Attendant Cases. Flight Attendant Cases are brought by non-smoking flight attendants alleging injury from exposure to environmental smoke in the cabins of aircraft. Plaintiffs in these cases may not seek punitive damages for injuries that arose prior to January 15, 1997. Lorillard Tobacco is a defendant in each of the approximately 2,625 pending Flight Attendant Cases. Lorillard, Inc. is not a defendant in any of these cases. The time for filing Flight Attendant Cases expired during 2000 and no additional cases in this category may be filed.

     Class Action Cases. Class Action Cases are purported to be brought on behalf of large numbers of individuals for damages allegedly caused by smoking. Eight of these cases are pending against Lorillard Tobacco. Lorillard, Inc. is a defendant in two of these eight cases. Two of the eight cases assert claims on behalf of purchasers of “light” cigarettes. Lorillard, Inc. is not a defendant in either of these cases. Neither Lorillard Tobacco nor Lorillard, Inc. is a defendant in the approximately 30 additional “lights” class actions that are pending against other cigarette manufacturers.

     Reimbursement Cases. Reimbursement Cases are brought by or on behalf of entities who seek reimbursement of expenses incurred in providing health care to individuals who allegedly were injured by smoking. Plaintiffs in these cases have included the U.S. federal government, U.S. state and local governments, foreign governmental entities, hospitals or hospital districts, American Indian tribes, labor unions, private companies and private citizens. Four such cases are pending against Lorillard Tobacco and other cigarette manufacturers in the United States and one such case is pending in Israel. Lorillard, Inc. is a defendant in two of the cases pending in the United States. Plaintiffs in the case in Israel have attempted to assert claims against Lorillard, Inc.

     Included in this category is the suit filed by the federal government, United States of America v. Philip Morris USA, Inc., et al., that sought return of profits and injunctive relief. In August 2006, the trial court issued its verdict and granted injunctive relief. The verdict did not award monetary damages. See “—Reimbursement Cases” below.

     Filter Cases. In addition to the above, Filter Cases are brought by individuals, including former employees of Lorillard Tobacco, who seek damages resulting from their alleged exposure to asbestos fibers that were incorporated into filter material used in one brand of cigarettes manufactured by Lorillard Tobacco for a limited period of time ending more than 50 years ago. Lorillard is a defendant in 30 Filter Cases. Lorillard Tobacco is a defendant in 29 such cases, including two cases in which Lorillard, Inc. is a defendant. Lorillard, Inc. is also a defendant in an additional Filter Case, in which Lorillard Tobacco is not a defendant.

     In addition to the above, Lorillard Tobacco and Lorillard, Inc. are named as defendants in one case in which it is alleged that a fire caused by a Lorillard cigarette led to an individual’s death.

     Plaintiffs assert a broad range of legal theories in these cases, including, among others, theories of negligence, fraud, misrepresentation, strict liability, breach of warranty, enterprise liability (including claims asserted under the federal Racketeering Influenced and Corrupt Organizations Act (“RICO”)), civil conspiracy, intentional infliction of harm, injunctive relief, indemnity, restitution, unjust enrichment, public nuisance, claims based on antitrust laws and state consumer protection acts, and claims based on failure to warn of the harmful or addictive nature of tobacco products.

     Plaintiffs in most of the cases seek unspecified amounts of compensatory damages and punitive damages, although some seek damages ranging into the billions of dollars. Plaintiffs in some of the cases seek treble damages, statutory damages, disgorgement of profits, equitable and injunctive relief, and medical monitoring, among other damages.

     Conventional Product Liability Cases

     As of April 27, 2009, approximately 155 cases are pending against cigarette manufacturers in the United States. Lorillard Tobacco is a defendant in approximately 35 of these cases. Lorillard, Inc. is a defendant in four of the pending cases. Lorillard Tobacco is a party to each of the cases in which Lorillard, Inc. is a defendant.

-10-

     Since January 1, 2007, verdicts have been returned in three cases. Neither Lorillard Tobacco nor Lorillard, Inc. was a defendant in any of these trials. A defense verdict was returned in one of the trials, and a jury found in favor of the plaintiffs and awarded damages in the other two trials. The defendants in the latter cases are pursuing appeals. In rulings addressing cases tried in earlier years, some appellate courts have reversed verdicts returned in favor of the plaintiffs while other judgments that awarded damages to smokers have been affirmed on appeal. Manufacturers have exhausted their appeals and have been required to pay damages to plaintiffs in nine individual cases in recent years. Punitive damages were paid to the smokers in three of the nine cases. Neither Lorillard Tobacco nor Lorillard, Inc. was a party to these nine matters.

     Some of the cases pending against cigarette manufacturers are scheduled for trial in 2009. Neither Lorillard Tobacco nor Lorillard, Inc. is a defendant in those cases. Trial dates are subject to change.

     Engle Progeny Cases

     Plaintiffs are individuals who allege they or their decedents are former members of the class that was decertified in Engle, a class action case that was pending in Florida. The 2006 ruling by the Florida Supreme Court that ordered decertification of the Engle class also permitted former class members to file individual actions, including claims for punitive damages. The court further held that these individuals are entitled to rely on a number of the jury’s findings in favor of the plaintiffs in the first phase of the Engle trial. The time period for filing Engle Progeny Cases expired in January 2008 and no additional cases may be filed. During 2009, the Florida Supreme Court rejected a petition that sought to extend the time for purported class members to file an additional lawsuit.

     As of April 27, 2009, Lorillard Tobacco was a defendant in approximately 3,200 cases filed by individuals who allege they or their decedents were members of the Engle class. Lorillard, Inc. is a defendant in approximately 1,075 of the pending cases. Lorillard Tobacco is a party to each of the cases in which Lorillard, Inc. is a defendant. Some of the suits are on behalf of multiple plaintiffs. Claims have been asserted by or on behalf of the estates of approximately 8,650 former class members in these 3,200 cases. In some cases, spouses of alleged former class members have also brought derivative claims.

     The Engle Progeny Cases are pending in various Florida state and federal courts. Some of these courts have issued rulings that address whether these individuals are entitled to rely on a number of the jury’s findings in favor of the plaintiffs in the first phase of the Engle trial. Some of these decisions have led to pending petitions for appeal. The U.S. Court of Appeals for the Eleventh Circuit agreed to review trial court rulings determining how courts should apply the Florida Supreme Court’s ruling regarding the Engle jury’s first phase verdict.

     As of April 27, 2009, Lorillard Tobacco was a defendant in several Engle Progeny Cases that have been placed on courts’ 2009 trial calendars or in which specific 2009 trial dates have been set. Lorillard, Inc. is a defendant in some of these cases. Trial schedules are subject to change and it is not possible to predict how many of the cases pending against Lorillard Tobacco or Lorillard, Inc. will be tried during 2009. It also is not possible to predict whether some courts will implement procedures that consolidate multiple Engle Progeny Cases for trial.

     As of April 27, 2009, trial was underway in two Engle Progeny cases. Neither Lorillard Tobacco nor Lorillard, Inc. is a defendant in these cases. Verdicts had been returned in three Engle Progeny cases since the Florida Supreme Court issued its 2006 ruling that permitted members of the Engle class to bring individual lawsuits. Neither Lorillard Tobacco nor Lorillard, Inc. was a defendant in these three trials. Juries awarded actual damages and punitive damages in one of the trials. In the other two trials, juries found in favor of the defendants that the plaintiffs were not former Engle class members. As of April 27, 2009, courts in two of the cases were considering post-trial motions, while the verdict in the third case has been appealed. In a case tried prior to the Florida Supreme Court’s 2006 decision permitting members of the Engle class to bring individual lawsuits, one Florida court allowed the plaintiff to rely at trial on certain of the Engle jury’s findings. That trial resulted in a verdict for the plaintiffs in which they were awarded approximately $25 million in actual damages. Neither Lorillard Tobacco nor Lorillard, Inc. was a party to this case. The defendants in this case are pursuing an appeal of the judgment, which was not entered until 2008.

     West Virginia Individual Personal Injury Cases

     The proceeding known as “West Virginia Individual Personal Injury Cases” consolidates for trial in a single West Virginia court a number of cases that have been filed against cigarette manufacturers, including Lorillard

-11-

Tobacco. The order that consolidated the cases, among other things, permitted only those cases filed by September 2000 to participate in the consolidated trial. As a result, no additional cases may be part of this proceeding.

     Approximately 1,250 cases became part of this proceeding, and Lorillard Tobacco was named in all but a few of them. Lorillard, Inc. was not a defendant in any of these cases. More than 500 of the cases have been dismissed in their entirety. Lorillard Tobacco has been dismissed from approximately 650 additional cases because those plaintiffs did not submit evidence that they had smoked a Lorillard Tobacco product. These 650 additional cases remain pending against other cigarette manufacturers and some or all the dismissals of Lorillard Tobacco could be contested in subsequent appeals noticed by the plaintiffs.

     As of April 27, 2009, approximately 730 cases were pending. Lorillard Tobacco is a defendant in approximately 55 of the pending cases. The court has entered a trial plan that calls for a multi-phase trial. The first phase of trial has been scheduled to begin on February 1, 2010. Trial dates are subject to change.

     Flight Attendant Cases

     Approximately 2,625 Flight Attendant Cases are pending. Lorillard Tobacco and three other cigarette manufacturers are the defendants in each of these matters. Lorillard, Inc. is not a defendant in any of these cases. These suits were filed as a result of a settlement agreement by the parties, including Lorillard Tobacco, in Broin v. Philip Morris Companies, Inc., et al. (Circuit Court, Miami-Dade County, Florida, filed October 31, 1991), a class action brought on behalf of flight attendants claiming injury as a result of exposure to environmental tobacco smoke. The settlement agreement, among other things, permitted the plaintiff class members to file these individual suits. These individuals may not seek punitive damages for injuries that arose prior to January 15, 1997. The period for filing Flight Attendant Cases expired during 2000 and no additional cases in this category may be filed.

     The judges that have presided over the cases that have been tried have relied upon an order entered during October 2000 by the Circuit Court of Miami-Dade County, Florida. The October 2000 order has been construed by these judges as holding that the flight attendants are not required to prove the substantive liability elements of their claims for negligence, strict liability and breach of implied warranty in order to recover damages. The court further ruled that the trials of these suits are to address whether the plaintiffs’ alleged injuries were caused by their exposure to environmental tobacco smoke and, if so, the amount of damages to be awarded.

     Lorillard Tobacco has been a defendant in each of the eight flight attendant cases in which verdicts have been returned. Defendants have prevailed in seven of the eight trials. In one of the seven cases in which a defense verdict was returned, the court granted plaintiff’s motion for a new trial and, following appeal, the case has been returned to the trial court for a second trial. The six remaining cases in which defense verdicts were returned are concluded. In the single trial decided for the plaintiff, French v. Philip Morris Incorporated, et al., the jury awarded $5.5 million in damages. The court, however, reduced this award to $500,000. This verdict, as reduced by the trial court, was affirmed on appeal and the defendants have paid the award. Lorillard Tobacco’s share of the judgment in this matter, including interest, was approximately $60,000. In addition, Lorillard Tobacco has paid its share of the attorneys’ fees, costs and post-judgment interest awarded to the plaintiff’s counsel in this matter. The court has ruled that Lorillard Tobacco will be required to pay approximately $290,000 in prejudgment interest on the award of attorneys’ fees Lorillard Tobacco previously paid in this matter. Pursuant to an agreement with the other defendants in this matter, Lorillard Tobacco expects that it will be reimbursed for approximately $190,000 of this amount should such award be sustained. Lorillard Tobacco has noticed an appeal from the order requiring it to pay post-judgment interest.

     As of April 27, 2009, none of the flight attendant cases are scheduled for trial. Trial dates are subject to change.

     Class Action Cases

     Lorillard Tobacco is a defendant in eight pending cases. Lorillard, Inc. is a defendant in two of these cases. Lorillard Tobacco is a party to both of the cases in which Lorillard, Inc. is a defendant. In most of the pending cases, plaintiffs seek class certification on behalf of groups of cigarette smokers, or the estates of deceased cigarette smokers, who reside in the state in which the case was filed.

     Cigarette manufacturers, including Lorillard Tobacco and Lorillard, Inc., have defeated motions for class certification in a total of 36 cases, 13 of which were in state court and 23 of which were in federal court. Motions for

-12-

class certification have also been ruled upon in some of the “lights” cases or in other class actions to which neither Lorillard Tobacco nor Lorillard, Inc. was a party. In some of these cases, courts have denied class certification to the plaintiffs, while classes have been certified in other matters.

     The Scott Case. In one of the class actions pending against Lorillard Tobacco, Scott v. The American Tobacco Company, et al. (District Court, Orleans Parish, Louisiana, filed May 24, 1996), the members of the class have been awarded damages. The defendants, including Lorillard Tobacco, have noticed an appeal from this award, which has been accepted for review by the Louisiana Court of Appeal, Fourth Circuit. The appeal is from the amended final judgment entered by the District Court in July 2008 that ordered defendants to pay approximately $264 million to fund a court-supervised cessation program for the members of the certified class. The amended final judgment also awards post-judgment judicial interest that will continue to accrue from June 2004 until the judgment either is paid or is reversed on appeal. As of April 27, 2009, judicial interest totaled approximately $95.2 million. Lorillard, Inc., which was a party to the case in the past, is no longer a defendant in Scott.

     During 1997, Scott was certified a class action on behalf of certain cigarette smokers resident in the State of Louisiana who desire to participate in medical monitoring or smoking cessation programs and who began smoking prior to September 1, 1988, or who began smoking prior to May 24, 1996 and allege that defendants undermined compliance with the warnings on cigarette packages.

     Trial in Scott was heard in two phases. At the conclusion of the first phase in July 2003, the jury rejected medical monitoring, the primary relief requested by plaintiffs, and returned sufficient findings in favor of the class to proceed to a Phase II trial on plaintiffs’ request for a statewide smoking cessation program. Phase II of the trial, which concluded during May 2004, resulted in an award of $591 million to fund cessation programs for Louisiana smokers.

     In February 2007, the Louisiana Court of Appeal reduced the amount of the award by approximately $328 million; struck an award of prejudgment interest, which totaled approximately $440 million as of December 31, 2006; and limited class membership to individuals who began smoking by September 1, 1988, and whose claims accrued by September 1, 1988. In January 2008, the Louisiana Supreme Court denied plaintiffs’ and defendants’ separate petitions for review. The U.S. Supreme Court denied defendants’ request that it review the case in May 2008. The case was returned to the trial court, which subsequently entered the amended final judgment. The defendants, including Lorillard Tobacco, have appealed the amended final judgment.

     Should the amended final judgment be sustained on appeal, Lorillard Tobacco’s share of that judgment, including the award of post-judgment interest, has not been determined. In the fourth quarter of 2007, Lorillard, Inc. recorded a pretax provision of approximately $66 million for this matter which was included in selling, general and administrative expenses on the consolidated statements of income and in other liabilities on the consolidated balance sheets.

     The parties filed a stipulation in the trial court agreeing that an article of Louisiana law required that the amount of the bond for the appeal be set at $50 million for all defendants collectively. The parties further agreed that the plaintiffs have full reservations of rights to contest in the trial court the sufficiency of the bond on any grounds. Defendants collectively posted a surety bond in the amount of $50 million, of which Lorillard Tobacco secured 25%, or $12.5 million. While Lorillard Tobacco believes the limitation on the appeal bond amount is valid as required by Louisiana law, in the event of a successful challenge the amount of the appeal bond could be set as high as 150% of the judgment and judicial interest combined. If such an event occurred, Lorillard Tobacco’s share of the appeal bond has not been determined.

     The Engle Case. The case of Engle v. R.J. Reynolds Tobacco Co., et al. (Circuit Court, Miami-Dade County, Florida, filed May 5, 1994), was certified as a class action on behalf of Florida residents, and survivors of Florida residents, who were injured or died from medical conditions allegedly caused by addiction to smoking. During 1999 and 2000, a jury returned verdicts that, among other things, awarded the certified class $145 billion in punitive damages, including $16.3 billion against Lorillard Tobacco. During 2006, the Florida Supreme Court vacated the punitive damages award, determined that the case could not proceed further as a class action and ordered decertification of the class. The trial court entered orders during 2008 that formally decertified the class. During July 2008, plaintiff voluntarily dismissed the case and Engle is no longer pending.

-13-

     The Florida Supreme Court’s 2006 decision also reinstated awards of actual damages to two of the three individuals whose claims were heard during the second phase of the Engle trial. One individual was awarded $3 million and the second was awarded $4 million. Both individuals informed the court that they would not seek punitive damages. These verdicts were paid during February 2008. Lorillard Tobacco’s payment was approximately $3.0 million for the verdicts and the interest that accrued since November 2000.

     Other Class Action Cases. In one of the cases pending against Lorillard Tobacco, Brown v. The American Tobacco Company, Inc., et al. (Superior Court, San Diego County, California, filed June 10, 1997), the court initially certified the case as a class action but it subsequently granted defendants’ motion for class decertification. The California Supreme Court heard plaintiffs’ appeal of the decertification order on March 3, 2009 and a ruling could be issued at any time. The class originally certified in Brown was composed of residents of California who smoked at least one of defendants’ cigarettes between June 10, 1993 and April 23, 2001 and who were exposed to defendants’ marketing and advertising activities in California.

     “Lights” Class Actions. Cigarette manufacturers are defendants in another group of approximately 30 cases in which plaintiffs’ claims are based on the allegedly fraudulent marketing of “light” or “ultra-light” cigarettes. Classes have been certified in some of these matters. In one of the pending “lights” cases, Good v. Altria Group, Inc., et al., the U.S. Supreme Court ruled that federal law does not prohibit plaintiffs from challenging statements authorized by the Federal Trade Commission about tar and nicotine yields that have been made in cigarette advertisements. Lorillard Tobacco is a defendant in one purported class action in which plaintiffs claims are limited to purchasers of “light” cigarettes, Schwab v. Philip Morris USA, Inc., et al., which is discussed below. In another case, Cleary v. Philip Morris Incorporated, et al., plaintiffs were permitted to amend their complaint in an existing class action in order to assert claims on behalf of a subclass of individuals who purchased “light” cigarettes from the defendants, including Lorillard Tobacco. Lorillard, Inc. is not a party to any of the purported “lights” class actions. A petition has been filed with the Judicial Panel on Multidistrict Litigation that proposes the transfer and consolidation of purported “lights” class actions in federal courts into a specially constituted court for pretrial proceedings. The eleven cases include the Cleary and Schwab cases that are pending against Lorillard Tobacco. As of April 27, 2009, the Judicial Panel had not issued a ruling in response to this application.

     The Schwab Case. In the case of Schwab v. Philip Morris USA, Inc., et al. (U.S. District Court, Eastern District, New York, filed May 11, 2004), plaintiffs base their claims on defendants’ alleged violations of the RICO statute in the manufacture, marketing and sale of “light” cigarettes. Plaintiffs estimated damages to the class in the hundreds of billions of dollars. Any damages awarded to the plaintiffs based on defendants’ violation of the RICO statute would be trebled. In September 2006, the court granted plaintiffs’ motion for class certification and certified a nationwide class action on behalf of purchasers of “light” cigarettes. In March 2008, the Second Circuit Court of Appeals reversed the class certification order and ruled that the case may not proceed as a class action. Schwab has been returned to the U.S. District Court for the Eastern District of New York for further proceedings, but the future activity in this matter, if any, is not known. Lorillard, Inc. is not a party to this case.

     Reimbursement Cases

     Lorillard Tobacco is a defendant in the four Reimbursement Cases that are pending in the U.S. and it has been named as a party to a case in Israel. Lorillard, Inc. is a co-defendant in two of the four cases pending in the U.S. Plaintiffs in the case in Israel have attempted to assert claims against Lorillard, Inc. In one of the cases, an order was entered dismissing the case, but the deadline for plaintiffs to notice an appeal of such order had not expired as of April 27, 2009.

     U.S. Federal Government Action. In August 2006, the U.S. District Court for the District of Columbia issued its final judgment and remedial order in the federal government’s reimbursement suit (United States of America v. Philip Morris USA, Inc., et al., U.S. District Court, District of Columbia, filed September 22, 1999). The verdict concluded a bench trial that began in September 2004. Lorillard Tobacco, other cigarette manufacturers, two parent companies and two trade associations are defendants in this action. Lorillard, Inc. is not a party to this case.

     In its 2006 verdict, the court determined that the defendants, including Lorillard Tobacco, violated certain provisions of the RICO statute, that there was a likelihood of present and future RICO violations, and that equitable relief was warranted. The government was not awarded monetary damages. The equitable relief included permanent injunctions that prohibit the defendants, including Lorillard Tobacco, from engaging in any act of racketeering,

-14-

as defined under RICO; from making any material false or deceptive statements concerning cigarettes; from making any express or implied statement about health on cigarette packaging or promotional materials (these prohibitions include a ban on using such descriptors as “low tar,” “light,” “ultra-light,” “mild” or “natural”); and from making any statements that “low tar,” “light,” “ultra-light,” “mild” or “natural” or low-nicotine cigarettes may result in a reduced risk of disease. The final judgment and remedial order also requires the defendants, including Lorillard Tobacco, to make corrective statements on their websites, in certain media, in point-of-sale advertisements, and on cigarette package “inserts” concerning: the health effects of smoking; the addictiveness of smoking; that there are no significant health benefits to be gained by smoking “low tar,” “light,” “ultra-light,” “mild” or “natural” cigarettes; that cigarette design has been manipulated to ensure optimum nicotine delivery to smokers; and that there are adverse effects from exposure to secondhand smoke. If the final judgment and remedial order are not modified or vacated on appeal, the costs to Lorillard Tobacco for compliance could exceed $10 million. Defendants have appealed to the U.S. Court of Appeals for the District of Columbia Circuit, which has stayed the judgment and remedial order while the appeal is proceeding. The government also has noticed an appeal from the final judgment. The Court of Appeals heard oral argument of the consolidated appeal in October 2008 and a ruling could be issued at any time. While trial was underway, the District of Columbia Court of Appeals ruled that plaintiff may not seek return of profits. In its present appeal, the government has preserved its right to seek review of this claim by the United States Supreme Court. Prior to trial, the government had estimated that it was entitled to approximately $280 billion from the defendants for its return of profits claim. In addition, the government sought during trial more than $10 billion for the creation of nationwide smoking cessation, public education and counter-marketing programs. In its 2006 verdict, the trial court declined to award such relief. It is possible that this claim could be reinstated on appeal.

     Settlement of State Reimbursement Litigation

     On November 23, 1998, Lorillard Tobacco, Philip Morris Incorporated, Brown & Williamson Tobacco Corporation and R.J. Reynolds Tobacco Company (the “Original Participating Manufacturers”) entered into the Master Settlement Agreement (“MSA”) with 46 states, the District of Columbia, the Commonwealth of Puerto Rico, Guam, the U.S. Virgin Islands, American Samoa and the Commonwealth of the Northern Mariana Islands to settle the asserted and unasserted health care cost recovery and certain other claims of those states. These settling entities are generally referred to as the “Settling States.” The Original Participating Manufacturers had previously settled similar claims brought by Mississippi, Florida, Texas and Minnesota, which together with the MSA are referred to as the “State Settlement Agreements.”

     The State Settlement Agreements provide that the agreements are not admissions, concessions or evidence of any liability or wrongdoing on the part of any party, and were entered into by the Original Participating Manufacturers to avoid the further expense, inconvenience, burden and uncertainty of litigation.

     Lorillard recorded pretax charges for its obligations under the State Settlement Agreements of $247 million and $257 million ($154 million and $162 million after taxes) for the three months ended March 31, 2009 and 2008, respectively. Lorillard’s portion of ongoing adjusted payments and legal fees is based on its share of domestic cigarette shipments in the year preceding that in which the payment is due. Accordingly, Lorillard records its portions of ongoing settlement payments as part of cost of manufactured products sold as the related sales occur.

     The State Settlement Agreements require that the domestic tobacco industry make annual payments of $9.4 billion, subject to adjustment for several factors, including inflation, market share and industry volume. In addition, the domestic tobacco industry is required to pay settling plaintiffs’ attorneys’ fees, subject to an annual cap of $500 million, as well as an additional amount of up to $125 million in each year through 2008. These payment obligations are the several and not joint obligations of each settling defendant.

     The State Settlement Agreements also include provisions relating to significant advertising and marketing restrictions, public disclosure of certain industry documents, limitations on challenges to tobacco control and underage use laws, and other provisions. Lorillard Tobacco and the other Original Participating Manufacturers have notified the States that they intend to seek an adjustment in the amount of payments made in 2003 pursuant to a provision in the MSA that permits such adjustment if the companies can prove that the MSA was a significant factor in their loss of market share to companies not participating in the MSA and that the States failed to diligently enforce certain statutes passed in connection with the MSA. If the Original Participating Manufacturers are ultimately successful, any adjustment would be reflected as a credit against future payments by the Original Participating Manufacturers under the agreement.

-15-

     From time to time, lawsuits have been brought against Lorillard Tobacco and other participating manufacturers to the MSA, or against one or more of the states, challenging the validity of the MSA on certain grounds, including as a violation of the antitrust laws. See "—MSA-Related Antitrust Suit” below.

     In addition, in connection with the MSA, the Original Participating Manufacturers entered into an agreement to establish a $5.2 billion trust fund payable between 1999 and 2010 to compensate the tobacco growing communities in 14 states (the “Trust”). Payments to the Trust will no longer be required as a result of an assessment imposed under a new federal law repealing the federal supply management program for tobacco growers, although the states of Maryland and Pennsylvania are contending that payments under the Trust should continue to growers in those states since the new federal law did not cover them, and the matter is being litigated. Under the new law, enacted in October 2004, tobacco quota holders and growers will be compensated with payments totaling $10.1 billion, funded by an assessment on tobacco manufacturers and importers. Payments to qualifying tobacco quota holders and growers commenced in 2005.

     Lorillard believes that the State Settlement Agreements will materially adversely affect its cash flows and operating income in future years. The degree of the adverse impact will depend, among other things, on the rates of decline in domestic cigarette sales in the premium price and discount price segments, Lorillard’s share of the domestic premium price and discount price cigarette segments, and the effect of any resulting cost advantage of manufacturers not subject to significant payment obligations under the State Settlement Agreements.

     Filter Cases

     In addition to the above, claims have been brought against Lorillard Tobacco and Lorillard, Inc. by individuals who seek damages resulting from their alleged exposure to asbestos fibers that were incorporated into filter material used in one brand of cigarettes manufactured by Lorillard Tobacco for a limited period of time ending more than 50 years ago. Lorillard Tobacco is a defendant in 29 such cases. Lorillard, Inc. is a defendant in three Filter Cases, including two that also name Lorillard Tobacco. Since January 1, 2007, Lorillard Tobacco has paid, or has reached agreement to pay, a total of approximately $14.2 million in settlements to finally resolve approximately 70 claims. The related expense was recorded in selling, general and administrative expenses on the consolidated statements of income. In the only such case tried since January 1, 2007, a jury in the District Court of Bexar County, Texas, returned a verdict for Lorillard Tobacco during September 2008 in the case of Young v. Lorillard Tobacco Company. As of April 27, 2009, eight of the Filter Cases were scheduled for trial. Trial dates are subject to change.

Tobacco-Related Antitrust Cases

     Indirect Purchaser Suits. Approximately 30 antitrust suits were filed in 2000 and 2001 on behalf of putative classes of consumers in various state courts against cigarette manufacturers, including Lorillard Tobacco. The suits all alleged that the defendants entered into agreements to fix the wholesale prices of cigarettes in violation of state antitrust laws which permit indirect purchasers, such as retailers and consumers, to sue under price fixing or consumer fraud statutes. More than 20 states permit such suits. Lorillard, Inc. was not named as a defendant in any of these cases. Lorillard Tobacco was a defendant in all but one of these indirect purchaser cases. Three indirect purchaser suits, in New York, Florida and Michigan, thereafter were dismissed by courts in those states, and the plaintiffs withdrew their appeals. The actions in all other states, except for New Mexico and Kansas, were voluntarily dismissed.

     In the Kansas case, the District Court of Seward County certified a class of Kansas indirect purchasers in 2002. In July 2006, the Court issued an order confirming that fact discovery was closed, with the exception of privilege issues that the Court determined, based on a Special Master’s report, justified further fact discovery. In October 2007, the Court denied all of the defendants’ privilege claims, and the Kansas Supreme Court thereafter denied a petition seeking to overturn that ruling. Discovery currently is ongoing. No date has been set by the Court for dispositive motions and trial.

     A decision granting class certification in New Mexico was affirmed by the New Mexico Court of Appeals in February 2005. As ordered by the trial court, class notice was sent out in October 2005. The New Mexico plaintiffs were permitted to rely on discovery produced in the Kansas case. In June 2006, the New Mexico trial court granted summary judgment to all defendants, and the suit was dismissed. An appeal was filed by the plaintiffs on August 14, 2006. The New Mexico Court of Appeals affirmed dismissal of all claims against Lorillard Tobacco in

-16-

December 2008, although claims against its major competitors were reinstated. Plaintiff has not sought to reinstate the claims against Lorillard Tobacco and the time for such action has expired. Accordingly, the New Mexico suit has now been concluded as against Lorillard Tobacco.

     MSA-Related Antitrust Suit. In October 2008, Lorillard Tobacco was named as a defendant in an action filed in the Western District of Kentucky, Vibo Corporation, Inc. d/b/a/ General Tobacco v. Conway, et al. The suit alleges that the named defendants, which include 52 state and territorial attorneys general and 19 tobacco manufacturers, violated the federal Sherman Antitrust Act of 1890 (the “Sherman Act”) by entering into and participating in the MSA. The plaintiff alleges that MSA participants, like it, that were not in existence when the MSA was executed in 1998 but subsequently became participants, are unlawfully required to pay significantly more sums to the states than companies that joined the MSA within 90 days after its execution. In addition to the Sherman Act claim, plaintiff has raised a number of constitutional claims against the states. Plaintiff seeks a declaratory judgment in its favor on all claims, an injunction against the continued enforcement of the MSA, treble damages against the tobacco manufacturer defendants, including Lorillard Tobacco and other manufacturer defendants, and damages and injunctive relief against the states, including contract recession and restitution. In December 2008, the court dismissed the complaint against all defendants, including Lorillard Tobacco. The court has not yet entered its final judgment. Accordingly, the time for plaintiff to appeal the decision has not yet expired.

Defenses

     Each of Lorillard Tobacco and Lorillard, Inc. believes that it has valid defenses to the cases pending against it as well as valid bases for appeal should any adverse verdicts be returned against either of them. Lorillard Tobacco is a defendant in approximately 5,900 pending product liability cases. Lorillard, Inc. is a co-defendant in approximately 1,085 of these cases. While Lorillard Tobacco and Lorillard, Inc. intend to defend vigorously all tobacco products liability litigation, it is not possible to predict the outcome of any of this litigation. Litigation is subject to many uncertainties. Plaintiffs have prevailed in several cases, as noted above. It is possible that one or more of the pending actions could be decided unfavorably as to Lorillard Tobacco, Lorillard, Inc. or the other defendants. Lorillard Tobacco and Lorillard, Inc. may enter into discussions in an attempt to settle particular cases if either believe it is appropriate to do so.

     Neither Lorillard Tobacco nor Lorillard, Inc. can predict the outcome of pending litigation. Some plaintiffs have been awarded damages from cigarette manufacturers at trial. While some of these awards have been overturned or reduced, other damages awards have been paid after the manufacturers have exhausted their appeals. These awards and other litigation activities against cigarette manufacturers continue to receive media attention. In addition, health issues related to tobacco products also continue to receive media attention. It is possible, for example, that the 2006 verdict in United States of America v. Philip Morris USA, Inc., et al., which made many adverse findings regarding the conduct of the defendants, including Lorillard Tobacco, could form the basis of allegations by other plaintiffs or additional judicial findings against cigarette manufacturers. In addition, the ruling in Good v. Altria Group, Inc., et al. could result in further “lights” litigation. Any such developments could have an adverse effect on the ability of Lorillard Tobacco or Lorillard, Inc. to prevail in smoking and health litigation and could influence the filing of new suits against Lorillard Tobacco or Lorillard, Inc. Lorillard Tobacco and Lorillard, Inc. also cannot predict the type or extent of litigation that could be brought against either of them, or against other cigarette manufacturers, in the future.

     Lorillard records provisions in the consolidated financial statements for pending litigation when it determines that an unfavorable outcome is probable and the amount of loss can be reasonably estimated. Except for the impact of the State Settlement Agreements and Scott as described above, management is unable to make a meaningful estimate of the amount or range of loss that could result from an unfavorable outcome of material pending litigation and, therefore, no material provision has been made in the consolidated financial statements for any unfavorable outcome. It is possible that Lorillard’s results of operations or cash flows in a particular quarterly or annual period or its financial position could be materially adversely affected by an unfavorable outcome or settlement of certain pending litigation.

Indemnification Obligations

     In connection with the Separation Lorillard entered into a separation agreement with Loews (the “Separation Agreement”) and agreed to indemnify Loews and its officers, directors, employees and agents against all costs and

-17-

expenses arising out of third party claims (including, without limitation, attorneys’ fees, interest, penalties and costs of investigation or preparation for defense), judgments, fines, losses, claims, damages, liabilities, taxes, demands, assessments and amounts paid in settlement based on, arising out of or resulting from, among other things, Loews’ ownership of or the operation of Lorillard and its assets and properties, and its operation or conduct of its businesses at any time prior to or following the Separation (including with respect to any product liability claims).

     Loews is a defendant in three pending product liability cases. One of these is a Reimbursement Case in Israel, while the two other cases are purported Class Action Cases on file in U.S. courts. Lorillard Tobacco also is a defendant in each of the three product liability cases in which Loews is involved. Pursuant to the Separation Agreement, Lorillard will be required to indemnify Loews for the amount of any losses and any legal or other fees with respect to such cases.

Other Litigation

     Lorillard is also party to other litigation arising in the ordinary course of business. The outcome of this other litigation will not, in the opinion of management, materially affect Lorillard’s results of operations or equity.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

          The following discussion should be read in conjunction with our historical consolidated financial statements and the notes related to those financial statements included in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 (the “Form 10-Q”). In addition to historical information, the following discussion contains forward-looking statements based on current expectations that involve risks and uncertainties. Investors are cautioned not to place undue reliance on these forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believe,” “expect,” “anticipate,” “intend,” “project,” “estimate,” “plan,” “may increase,” “may fluctuate” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and are not historical facts. Actual results and the timing of certain events may differ significantly from those projected in such forward-looking statements due to a number of factors, including those risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2008 (the “Form 10-K”) and those risk factors set forth in “Business Environment” below, in Part II, “Item 1A. Risk Factors” and elsewhere in this Form 10-Q. Except for our ongoing obligations to disclose material information under the federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events unless required by law. For any forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Our consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (“GAAP”).

          The terms “Lorillard,” “we,” “our” and “us” refer to Lorillard, Inc., a Delaware corporation, and its subsidiaries. The terms “Lorillard, Inc.” and the “Company” refer solely to the parent company and “Lorillard Tobacco” refers solely to Lorillard Tobacco Company, the principal subsidiary of Lorillard, Inc.

Overview

          We are the third largest manufacturer of cigarettes in the United States. We were founded in 1760 and are the oldest continuously operating tobacco company in the United States. Newport, which is our flagship brand, is a menthol flavored premium cigarette brand and the top selling menthol and second largest selling cigarette brand overall in the United States based on gross units sold in the first three months of 2009 and in the full year 2008. In addition to the Newport brand, our product line has five additional brand families marketed under the Kent, True, Maverick, Old Gold and Max brand names. These six brands include 44 different product offerings which vary in price, taste, flavor, length and packaging. In the United States and certain U.S. possessions and territories, we shipped 7.9 billion cigarettes in the first three months of 2009 and 37.8 billion cigarettes for full year 2008. Our major trademarks outside of the United States were sold in 1977. We manufacture all of our products at our Greensboro, North Carolina facility.

-18-

Critical Accounting Policies and Estimates

          For a description of the critical accounting policies that require the use of significant judgments and estimates by management, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Form 10-K filed with the Securities and Exchange Commission on March 2, 2009.

Business Environment

          Participants in the U.S. tobacco industry, including us, face a number of issues that have adversely affected their results of operations and financial condition in the past and will continue to do so, including:

• A substantial volume of litigation seeking compensatory and punitive damages ranging into the billions of dollars, as well as equitable and injunctive relief, arising out of allegations of cancer and other health effects resulting from the use of cigarettes, addiction to smoking or exposure to environmental tobacco smoke, including claims for economic damages relating to alleged misrepresentation concerning the use of descriptors such as “lights,” as well as other alleged damages.

• Substantial annual payments continuing in perpetuity, and significant restrictions on marketing and advertising have been agreed to and are required under the terms of certain settlement agreements, including the Master Settlement Agreement among major tobacco manufacturers and 46 states and various other governments and jurisdictions (the “MSA”) that we entered into in 1998 along with Philip Morris Incorporated, Brown & Williamson Tobacco Corporation and R.J. Reynolds Tobacco Company (the other “Original Participating Manufacturers”) to settle asserted and unasserted health care cost recovery and other claims. We and certain other U.S. tobacco product manufacturers previously settled similar claims brought by Mississippi, Florida, Texas and Minnesota (the “Initial State Settlements,” and together with the MSA, the “State Settlement Agreements”). The State Settlement Agreements impose a stream of future payment obligations on us and the other major U.S. cigarette manufacturers and place significant restrictions on their ability to market and sell cigarettes.

• The continuing contraction of the domestic cigarette market, in which we currently conduct our only significant business. As a result of price increases, restrictions on advertising, promotions and smoking in public and private facilities, increases in regulation and excise taxes, health concerns, a decline in the social acceptability of smoking, increased pressure from anti-tobacco groups and other factors, domestic cigarette shipments have decreased at a compound rate of approximately 2.6% from the twelve months ended March 31, 1999 through the twelve months ended March 31, 2009.

• Increases in cigarette prices since 1998 have led to an increase in the volume of discount and, specifically, deep discount cigarettes. Cigarette price increases have been driven by increases in state and local excise taxes and by manufacturer price increases. Price increases have led, and continue to lead, to high levels of discounting and other promotional activities for premium brands. Deep discount brands have grown from an estimated share in 1998 of less than 1.5% to an estimated 14.3% for the three months ended March 31, 2009, and continue to be a significant competitive factor in the domestic market. We do not have sufficient empirical data to determine whether the increased price of cigarettes has deterred consumers from starting to smoke or encouraged them to quit smoking, but it is likely that increased prices may have had an adverse effect on consumption and may continue to do so.

• Substantial and increasing regulation of the tobacco industry and government restrictions on smoking. In recent years, states and many local and municipal governments and agencies, as well as private businesses, have adopted legislation, regulations or policies which prohibit, restrict or discourage smoking, including legislation, regulations or policies prohibiting or restricting smoking in public buildings and facilities, stores, restaurants and bars, on airline flights and in the workplace. Other similar laws and regulations are currently under consideration and may be enacted by state and local governments in the future. A bill was introduced in March 2009 in the

-19-

U.S. Congress to grant the Food and Drug Administration (“FDA”) authority to regulate tobacco products. The bill was approved by the House of Representatives in April 2009 and may be considered by the Senate later this year. If the bill is enacted into law, we believe that the FDA could promulgate regulations that could among other things result in a ban on or restrict the use of menthol in cigarettes. The bill would impose new restrictions on the manner in which cigarettes can be advertised and marketed, require larger and more severe health warnings on cigarette packaging, restrict the level of tar and nicotine contained in or yielded by cigarettes and may alter the way cigarette products are developed and manufactured. We also believe that the bill, if enacted, would provide our larger competitors with a competitive advantage.

• Substantial federal, state and local excise taxes which are reflected in the retail price of cigarettes. For the three months ended March 31, 2009, the federal excise tax was $0.39 per pack and combined state and local excise taxes ranged from $0.07 to $4.25 per pack. For the three months ended March 31, 2009, an excise tax increase of $0.56 per pack was implemented in one state. Congress recently enacted and the President signed into law an increase in the federal excise tax on cigarettes by $0.6166 per pack to $1.0066 per pack, effective April 1, 2009, to finance health insurance for children. It is likely that increases in excise and similar taxes have had an adverse impact on sales of cigarettes and that the most recent increase and future increases, the extent of which cannot be predicted, could result in further volume declines for the cigarette industry, including us, and an increased sales shift toward deep discount cigarettes rather than premium brands. In addition, we and other cigarette manufacturers and importers are required to pay an assessment under a federal law designed to fund payments to tobacco quota holders and growers.

          In December 2008, the Federal Trade Commission (the “FTC”) issued a statement withdrawing its previous guidance allowing the use of the term “FTC method” to identify the testing protocol used by cigarette manufacturers to ascertain the tar and nicotine yields of cigarettes on advertising. The statement also set forth the FTC’s position that it considered the use of certain descriptors like “lights” and “medium” in connection with the marketing and sale of cigarettes to be misleading consumers to believe that such cigarettes are safer than other cigarettes not bearing such descriptors. As a result of such statement, we will no longer list tar and nicotine yield information in our advertising and will include a statement that the use of certain descriptors on our packaging and advertising does not mean that the cigarette in question is any safer than any other flavor or style of cigarette.

          The domestic market for cigarettes is highly competitive. Competition is primarily based on a brand’s price, including the level of discounting and other promotional activities, positioning, consumer loyalty, retail display, quality and taste. Our principal competitors are the two other major U.S. cigarette manufacturers, Philip Morris USA Inc. (“Philip Morris”), a subsidiary of Altria Group, Inc., and R.J. Reynolds Tobacco Company (“Reynolds”), a subsidiary of Reynolds American Inc. We also compete with numerous other smaller manufacturers and importers of cigarettes, including deep discount cigarette manufacturers. We believe our ability to compete even more effectively has been restrained in some marketing areas as a result of retail merchandising contracts offered by Philip Morris and RAI which limit the retail shelf space available to our brands. As a result, in some retail locations we are limited in competitively supporting our promotional programs, which may constrain sales.

-20-

          The following table presents Lorillard’s selected industry and market share data for the three months ended March 31, 2009 and 2008.

Selected Industry and Market Share Data (1)

	Three Months Ended
	March 31,
	2009		2008
Lorillard total domestic unit volume (in billions)		7.7		8.4
Industry total domestic unit volume		72.0		80.4
Lorillard’s share of the domestic market		10.7		10.5
Lorillard’s premium volume as a percentage of its domestic volume		90.3		93.3
Lorillard’s share of the premium market		13.6		13.3
Newport’s share of the domestic market		9.5		9.5
Newport’s share of the premium market		13.3		13.0
Total menthol segment market share for the industry		28.7		28.4
Total discount segment market share for the industry		28.5		26.9
Newport’s share of the menthol market		33.1		33.5
Newport’s share of Lorillard’s total volume(2)		88.8		91.1
Newport’s share of Lorillard’s net sales(2)		93.2		94.1

(1)

Source: Management Science Associates, Inc. (“MSAI”), an independent third-party database management organization that collects wholesale shipment data from various cigarette manufacturers. MSAI divides the cigarette market into two price segments, the premium price segment and the discount or reduced price segment. MSAI’s information relating to unit sales volume and market share of certain of the smaller, primarily deep discount, cigarette manufacturers is based on estimates derived by MSAI. Management believes that volume and market share information for deep discount manufacturers may be understated and, correspondingly, market share information for the larger manufacturers, including Lorillard Tobacco, may be overstated by MSAI.

(2)

Source: Lorillard shipment reports.

Result of Operations

Three Months Ended March 31, 2009 Compared to the Three Months Ended March 31, 2008

	Three Months Ended
	March 31,
	2009		2008
	(In millions)
Net sales (including excise taxes of $150 and $163, respectively)	$	917	$	921
Cost of sales		532		555
Gross profit		385		366
Selling, general and administrative		91		100
Operating income		294		266
Other income, net		1		9
Income before income taxes		295		275
Income taxes		111		101
Net income	$	184	$	174

          Net sales. Net sales decreased by $4 million, or 0.4%, from $921 million for the three months ended March 31, 2008 to $917 million for the three months ended March 31, 2009. Net sales decreased $98 million due to lower unit sales volume and $12 million due to higher sales incentives, partially offset by higher average unit prices of $106 million reflecting price increases in May and December 2008 and February and March 2009. Federal excise

-21-

taxes are included in net sales and have remained constant at $19.50 per thousand units, or $0.39 per pack of 20 cigarettes, since January 1, 2002.

          Our total unit volume decreased 7.6% and domestic unit volume decreased 8.2% during the three months ended March 31, 2009 compared to the corresponding period of 2008. Unit volume figures in this section are provided on a gross basis. Total Newport unit volume decreased 9.9% and domestic Newport volume decreased 10.6% during the three months ended March 31, 2009 compared to the corresponding period of 2008. Industry-wide domestic unit volume decreased 10.4% during the three months ended March 31, 2009 compared to the corresponding period of 2008. Industry shipments of premium brands comprised 71.5% of industry-wide domestic unit volume during the three months ended March 31, 2009 and 73.1% in the corresponding period of 2008.

          Wholesale shipment volume in the first quarter of 2009 compared to the same quarter of 2008 for Lorillard and for the total industry was negatively impacted by tax-driven trade purchasing patterns in anticipation of the $0.62 increase in the federal excise tax on cigarettes from $0.39 to $1.01 per pack on April 1, 2009. This legislation included provisions that imposed this increase in excise taxes on inventory held as of March 31, 2009 (a “floor tax”). As a result, many wholesalers and retailers depleted their inventory levels as of that date to minimize any such floor taxes owed based on inventory. Additionally, the first quarter of 2009 contained one less shipping day than the first quarter of 2008. We believe that trade inventories will return to levels closer to historical averages during future periods.

          Cost of sales. Cost of sales decreased by $23 million, or 4.1%, from $555 million for the three months ended March 31, 2008 to $532 million for the three months ended March 31, 2009. The decrease in cost of sales is primarily attributed to lower expenses related to the State Settlement Agreements. We recorded charges for our obligations under the State Settlement Agreements of $247 million and $257 million for the three months ended March 31, 2009 and 2008, respectively, a decrease of $10 million. The $10 million decrease is due to lower unit sales ($20 million), partially offset by the impact of the inflation adjustment ($7 million) and by higher other adjustments ($3 million). Lower unit sales resulted in $13 million of lower federal excise taxes.

          Selling, general and administrative. Selling, general and administrative expenses decreased $9 million, or 9.0%, from $100 million for the three months ended March 31, 2008 to $91 million for the three months ended March 31, 2009. The decrease was primarily due to lower marketing costs of $5 million in the first quarter of 2009 and a $13 million charge in the first quarter of 2008 related to the separation of Lorillard from Loews, partially offset by an increase in legal expenses of $9 million for the three months ended March 31, 2009. The $9 million increase was primarily due to increased legal fees related to the Engle Progeny Cases.

          Other income, net. Other income, net decreased $8 million, or 88.9%, from $9 million for the three months ended March 31, 2008 to $1 million for the three months ended March 31, 2009. The decrease in other income, net primarily reflects lower interest rates for the three months ended March 31, 2009 compared to the corresponding period of 2008.

          Income taxes. Income taxes increased by $10 million, or 9.9%, from $101 million for the three months ended March 31, 2008 to $111 million for the three months ended March 31, 2009. The change reflects the increase in income before income taxes of $20 million in 2009, or 7.3%, and an increase in the effective tax rate from 36.8% in the first quarter of 2008 to 37.7% in the first quarter of 2009. This increase in the effective tax rate impacts income tax expense by $3 million, and is primarily the result of an increase in state tax rates in 2009.

Liquidity and Capital Resources

          Our cash and cash equivalents, and investments, net of receivables and payables, totaled $1,513 million and $1,220 million at March 31, 2009 and December 31, 2008, respectively. At March 31, 2009, 98.9% of our cash and investments were invested in short-term securities that included $1,327 million in government money market funds and $155 million in repurchase agreements with various financial institutions, which agreements are collateralized by treasury securities on deposit with the Company equal to 102% of the principal investment.

-22-

Cash Flows

          Cash flow from operating activities. The principal source of liquidity for our business and operating needs is internally generated funds from our operations. We generated net cash flow from operations of $453 million for the three months ended March 31, 2009 compared to $499 million for the three months ended March 31, 2008. The decreased cash flow in 2009 reflects higher inventory, partially offset by timing differences related to cash payments of estimated taxes.

          Cash flow from investing activities. Our cash flow from investing activities used cash of $10 million for the three months ended March 31, 2009 compared to $611 million in the three months ended March 31, 2008. The decrease in cash flow used in investing activities in 2009 is primarily due to a decrease in the level of investment purchases and sales.

          During the first three months of 2009, capital expenditures were $10 million compared to $7 million for the corresponding period of 2008. The expenditures were primarily for the modernization of manufacturing equipment. Our capital expenditures for 2009 are forecast to be between $50 million and $60 million.

          Cash flow from financing activities. Our cash flow from operations has exceeded our working capital and capital expenditure requirements during the first three months of 2009. We paid cash dividends to Loews of $291 million on January 24, 2008 and cash dividends of $155 million to shareholders on March 12, 2009.

Liquidity

          We believe that cash flow from operating activities will be sufficient for the foreseeable future to enable us to meet our obligations under the State Settlement Agreements and to fund our working capital and capital expenditure requirements. We cannot predict our cash requirements related to any future settlements or judgments, including cash required to bond any appeals, if necessary, and can make no assurance that we will be able to meet all of those requirements.

          Other than commercial obligations incurred in the ordinary course of business, we have no indebtedness for borrowed money. We believe that it would be appropriate for a company of our size and financial characteristics to have a prudent level of debt as a component of its capital structure in order to reduce its total cost of capital and improve total stockholder returns. Accordingly, we expect to raise between $750 million and $1.0 billion of debt financing, although the structure, timing and amount of such indebtedness has not yet been determined and will depend on a number of factors, including, but not limited to, the credit and interest rate environment, our cash requirements and other business, financial and tax considerations. The proceeds of any such debt financing may be used to fund stock repurchases, acquisitions, dividends or for other general corporate purposes. We presently have no commitments or agreements with or from any third party regarding any debt financing transaction and no assurance can be given that we will ultimately pursue any debt financing or, if pursued, that we will be able to obtain debt financing at the anticipated levels or on attractive terms.

State Settlement Agreements

          The State Settlement Agreements require us and the other Original Participating Manufacturers (Philip Morris Incorporated, Brown & Williamson Tobacco Corporation and R.J. Reynolds Tobacco Company) to make aggregate annual payments of $10.4 billion in perpetuity, subject to adjustment for several factors described below. In addition, the Original Participating Manufacturers are required to pay plaintiffs’ attorneys’ fees, subject to an aggregate annual cap of $500 million, as well as an additional aggregate amount of up to $125 million in each year through 2008. These payment obligations are several and not joint obligations of each of the Original Participating Manufacturers. Our obligations under the State Settlement Agreements will materially adversely affect our cash flows and operating income in future years.

          Both the aggregate payment obligations of the Original Participating Manufacturers, and our payment obligations, individually, under the State Settlement Agreements are subject to adjustment for several factors which include:

-23-

• inflation;

• aggregate volume of Original Participating Manufacturers cigarette shipments;

• other Original Participating Manufacturers and our market share; and

• aggregate Original Participating Manufacturers operating income, allocated to such manufacturers that have operating income increases.

          The inflation adjustment increases payments on a compounded annual basis by the greater of 3.0% or the actual total percentage change in the consumer price index for the preceding year. The inflation adjustment is measured starting with inflation for 1999. The volume adjustment increases or decreases payments based on the increase or decrease in the total number of cigarettes shipped in or to the 50 U.S. states, the District of Columbia and Puerto Rico by the Original Participating Manufacturers during the preceding year compared to the 1997 base year shipments. If volume has increased, the volume adjustment would increase the annual payment by the same percentage as the number of cigarettes shipped exceeds the 1997 base number. If volume has decreased, the volume adjustment would decrease the annual payment by 98.0% of the percentage reduction in volume. In addition, downward adjustments to the annual payments for changes in volume may, subject to specified conditions and exceptions, be reduced in the event of an increase in the Original Participating Manufacturers aggregate operating income from domestic sales of cigarettes over base year levels established in the State Settlement Agreements, adjusted for inflation. Any adjustments resulting from increases in operating income would be allocated among those Original Participating Manufacturers which have had increases.

          In April 2009, we paid $856 million under the State Settlement Agreements, primarily based on 2008 volume. In addition, in April 2009, we deposited $69 million, in an interest-bearing escrow account in accordance with procedures established in the MSA pending resolution of a claim by us and the other Original Participating Manufacturers that they are entitled to reduce their MSA payments based on a loss of market share to non-participating manufacturers. Most of the states that are parties to the MSA are disputing the availability of the reduction and we believe that this dispute will ultimately be resolved by judicial and arbitration proceedings. Our $69 million reduction is based upon the Original Participating Manufacturers collective loss of market share in 2006. In April of 2008, 2007 and 2006, we had previously deposited $72 million, $111 million and $109 million, respectively, in the same escrow account discussed above, which was based on a loss of market share in 2005, 2004 and 2003 to non-participating manufacturers. In February 2009, we directed the transfer of $72 million from this account to the non-disputed account, related to the loss of market share in 2005, pursuant to an Agreement Concerning Arbitration that we and other Participating Manufacturers entered into with certain MSA states. This amount was then paid to the MSA states. We and the other Original Participating Manufacturers have the right to claim additional reductions of MSA payments in subsequent years under provisions of the MSA. In addition to the payments made in the first four months of 2009, we anticipate the additional amount payable in 2009 will be approximately $200 million to $210 million, primarily based on 2009 estimated volume.

Contractual Cash Payment Obligations

          The following chart presents our contractual cash payment obligations as of March 31, 2009.

			Less than						More than
	Total		1 year		1-3 years		3-5 years		5 years
	(In millions)
Tobacco leaf purchase obligations	$	340	$	208	$	115	$	17	$	—
Operating lease obligations		4		1		3		—		—
Purchase obligations		70		68		2		—		—
Total	$	414	$	277	$	120	$	17	$	—

          In addition to the obligations presented in the table above, as of March 31, 2009, we believe that it is reasonably possible that payments of up to $2 million may be made to various tax authorities in the next twelve months

-24-

related to gross unrecognized tax benefits. We cannot make a reasonably reliable estimate of the amount of liabilities for unrecognized tax benefits that may result in cash settlements for periods beyond twelve months.

          As previously discussed, we have entered into the State Settlement Agreements, which impose a stream of future payment obligations on us and the other major U.S. cigarette manufacturers. Our portion of ongoing adjusted settlement payments, including fees to settling plaintiffs’ attorneys, is based on a number of factors which are described above. Our cash payment under the State Settlement Agreements in 2008 amounted to $1.08 billion and we estimate our cash payments in 2009 under the State Settlement Agreements will be between $1.12 billion and $1.13 billion, primarily based on 2008 estimated industry volume. Payment obligations are not incurred until the related sales occur and therefore are not reflected in the above table.

Off-Balance Sheet Arrangements

          None.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Market Risk

          We invest in financial instruments that involve market risk. Our measure of market risk exposure represents an estimate of the change in fair value of our financial instruments. Market risk exposure is presented below for each class of financial instrument we held at March 31, 2009, assuming immediate adverse market movements of the magnitude described below. We believe that the rate of adverse market movement represents a measure of exposure to loss under hypothetically assumed adverse conditions. The estimated market risk exposure represents the hypothetical loss to future earnings and does not represent the maximum possible loss nor any expected actual loss, even under adverse conditions, because actual adverse fluctuations would likely differ. In addition, since our investment portfolio is subject to change based on its portfolio management strategy as well as in response to changes in the market, these estimates are not necessarily indicative of the actual results which may occur. The market risk exposure represents the potential loss in carrying value and pretax impact to future earnings caused by the hypothetical change in price.

          Exposure to market risk is managed and monitored by senior management. Senior management approves our overall investment strategy and has the responsibility to ensure that the investment positions are consistent with that strategy with an acceptable level of risk.

          Interest rate risk. Our investments, which are included in cash and cash equivalents, consist of government money market funds and repurchase agreements with financial institutions, which agreements are collateralized by treasury securities on deposit with the Company equal to 102% of the principal investment. Those investments are exposed to fluctuations in interest rates. A sensitivity analysis, based on a hypothetical 1% increase or decrease in interest rates on our average 2009 investments, would cause an increase or decrease in pretax income of approximately $4 million for the three months ended March 31, 2009.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

          Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a—15 under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) as of the end of the period covered by this Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Form 10-Q, our disclosure controls and procedures (as defined in Rule 13a—15(e) under the Exchange Act) are effective, in all material respects, to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

-25-

Changes in Internal Control over Financial Reporting

          No change in our internal control over financial reporting (as defined in Rule 13a—15(f) under the Exchange Act) occurred during our most recent fiscal quarter that has materially affected, or is likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

          Information about legal proceedings is set forth in Note 9, “Legal Proceedings and Commitments ¯ Legal Proceedings,” in the Notes to Consolidated Condensed Financial Statements included in “Item 1. Financial Statements” of this Form 10-Q. Such information is incorporated by reference as if fully set forth herein.

Item 1A. Risk Factors.

With the exception of the following, there have been no other material changes in our risk factors from those disclosed in Part I, Item 1A of our Form 10-K:

As of April 27, 2009, Lorillard Tobacco is a defendant in approximately 5,900 tobacco-related lawsuits, including approximately 1,085 cases in which Lorillard, Inc. is a co-defendant. These cases, which are extremely costly to defend, could result in substantial judgments against Lorillard Tobacco and/or Lorillard, Inc.

          Numerous legal actions, proceedings and claims arising out of the sale, distribution, manufacture, development, advertising, marketing and claimed health effects of cigarettes are pending against Lorillard Tobacco and Lorillard, Inc., and it is likely that similar claims will continue to be filed for the foreseeable future. In addition, several cases have been filed against Lorillard Tobacco and other tobacco companies challenging certain provisions of the Master Settlement Agreement among major tobacco manufacturers and 46 states and various other governments and jurisdictions (the “MSA”), and state statutes promulgated to carry out and enforce the MSA.

          Punitive damages, often in amounts ranging into the billions of dollars, are specifically pleaded in a number of cases in addition to compensatory and other damages. It is possible that the outcome of these cases, individually or in the aggregate, could result in bankruptcy. It is also possible that Lorillard Tobacco and Lorillard, Inc. may be unable to post a surety bond in an amount sufficient to stay execution of a judgment in jurisdictions that require such bond pending an appeal on the merits of the case. Even if Lorillard Tobacco and Lorillard, Inc. are successful in defending some or all of these actions, these types of cases are very expensive to defend. A material increase in the number of pending claims could significantly increase defense costs and have an adverse effect on our results of operation and financial condition. Further, adverse decisions in litigations against other tobacco companies could have an adverse impact on the industry, including us.

The Florida Supreme Court’s ruling in Engle has resulted in additional litigation against cigarette manufacturers, including us.

          The case of Engle v. R.J. Reynolds Tobacco Co., et al. (Circuit Court, Dade County, Florida, filed May 5, 1994) was certified as a class action on behalf of Florida residents, and survivors of Florida residents, who were injured or died from medical conditions allegedly caused by addiction to smoking. The case was tried between 1998 and 2000 in a multi-phase trial that resulted in verdicts in favor of the class. During 2006, the Florida Supreme Court issued a ruling that, among other things, determined that the case could not proceed further as a class action. In February 2008, the trial court entered an order on remand from the Florida Supreme Court that formally decertified the class.

          The 2006 ruling by the Florida Supreme Court in Engle also permitted members of the Engle class to file individual claims, including claims for punitive damages. The Florida Supreme Court held that these individual plaintiffs are entitled to rely on a number of the jury’s findings in favor of the plaintiffs in the first phase of the Engle trial. These findings included that smoking cigarettes causes a number of diseases; that cigarettes are addictive or

-26-

dependence-producing; and that the defendants, including Lorillard Tobacco and Lorillard, Inc., were negligent, breached express and implied warranties, placed cigarettes on the market that were defective and unreasonably dangerous, and concealed or conspired to conceal the risks of smoking. Lorillard Tobacco is a defendant in approximately 3,200 cases pending in various state and federal courts in Florida that were filed by members of the Engle class (the “Engle Progeny Cases”), including approximately 1,075 cases in which Lorillard, Inc. is a co-defendant. These 3,200 cases are filed on behalf of approximately 8,650 individual plaintiffs.

          As of April 27, 2009, Lorillard Tobacco was a defendant in several Engle Progeny Cases that have been placed on courts’ 2009 trial calendars or in which specific 2009 trial dates have been set. Lorillard, Inc. is a defendant in some of these cases. Trial schedules are subject to change and it is not possible to predict how many of the Engle Progeny Cases pending against Lorillard Tobacco or Lorillard, Inc. will be tried during 2009. It also is not possible to predict whether some courts will implement procedures that consolidate multiple Engle Progeny Cases for trial.

Lorillard Tobacco is a defendant in a case that was initially certified as a nationwide class action involving “lights” cigarettes and that could result in a substantial verdict, if the class certification order is reinstated.

          Schwab v. Philip Morris USA, Inc., et al. (U.S. District Court, Eastern District, New York, filed May 11, 2004), was certified by a federal judge as a nationwide class action on behalf of individuals who purchased “light” cigarettes. Plaintiffs’ claims in Schwab are based on defendants’ alleged RICO violations in the manufacture, marketing and sale of “light” cigarettes. Plaintiffs have estimated damages to the class to be in the hundreds of billions of dollars. Any damages awarded to the plaintiffs based on defendants’ violation of the RICO statute would be multiplied by a factor of three. In March 2008, a federal court of appeals reversed the class certification ruling. Plaintiffs did not seek further review of this decision and the case has been returned to the Eastern District of New York for further proceedings. Schwab is one of a number of cases pending in federal courts that are the subject of a petition seeking the transfer and consolidation of certain purported “lights” class action cases into a specially constituted court for pretrial proceedings. As of April 27, 2009, the petition has not been decided by the Judicial Panel on Multidistrict Litigation before which it is pending. We cannot predict future activity in this case.

The proposed regulation of cigarettes by the Food and Drug Administration may adversely affect our
business.

          A bill that would grant the FDA authority to regulate tobacco products has been introduced in U.S. Congress and was approved by the House of Representatives in April 2009. The bill, which is being supported by Philip Morris and opposed by us and RAI, may be considered by the Senate later during this Congressional session. The proposed bill would:

§	establish a Tobacco Scientific Advisory Panel to evaluate the issues surrounding the use of menthol as a flavoring or ingredient in cigarettes;
§	require larger and more severe health warnings on packs and cartons;
§	ban the use of descriptors on tobacco products, such as “low-tar” and “light”;
§	require the disclosure of ingredients and additives to consumers;
§	require pre-market approval by the FDA for claims made with respect to reduced risk or reduced exposure products;
§	require the reduction or elimination of nicotine or any other compound in cigarettes;
§	allow the FDA to mandate the use of reduced risk technologies in conventional cigarettes;
§	allow the FDA to place more severe restrictions on the advertising, marketing and sales of cigarettes;
§	permit inconsistent state regulation of labeling and advertising and eliminate the existing federal preemption of such regulation; and
§	grant the FDA the regulatory authority to consider and impose broad additional restrictions through a rule making process, including a ban on the use of menthol in cigarettes.

          It is possible that such additional regulation could result in a decrease in cigarette sales in the United States (including sales of our brands) and increased costs to us, which may have a material adverse effect on our financial condition, results of operations, and cash flows. We believe that such regulation may adversely affect our ability to

-27-

compete against our larger competitors, including Philip Morris, who may be able to more quickly and cost-effectively comply with these new rules and regulations.

Concerns that mentholated cigarettes may pose greater health risks could adversely affect our business.

          Some plaintiffs and other sources, including public health agencies, have claimed or expressed concerns that mentholated cigarettes may pose greater health risks than non-mentholated cigarettes, including concerns that menthol cigarettes may make it easier to start smoking and harder to quit. For example, in June 2008, seven former U.S. health secretaries criticized a bill then under consideration in the House of Representatives to grant the FDA the authority to regulate tobacco products and ban the use of characterizing flavors other than menthol in cigarettes. The former health secretaries argued that the menthol exemption discriminates against African-American smokers who often prefer menthol cigarettes and have higher rates of some smoking-related diseases. In the course of consideration of the bill by a committee of the House of Representatives in 2008, an amendment was offered and rejected which would have banned the use of menthol as an ingredient in cigarettes. The final bill passed by the House in July 2008 and again in April 2009 included a provision establishing a Tobacco Scientific Advisory Panel to evaluate issues surrounding the use of menthol as a flavoring or ingredient in cigarettes within one year of such Panel’s establishment. The bill also would permit the FDA to ban menthol upon a finding that such prohibition would be appropriate for the public health. Prior to these developments, in 2002 the U.S. Department of Health and Human Services National Institutes of Health, Center for Disease Control and Prevention and National Cancer Institute and other public health agencies supported the First Conference on Menthol Cigarettes. The executive summary of the conference proceedings outlined “why it is important to study menthol cigarettes” and included statements that “menthol’s sensation of coolness might result in deeper inhalation” and “could contribute to increased uptake of inhaled tobacco constituents, including nicotine and cancer-causing agents...” In addition, the Center for Disease Control and Prevention has published a pamphlet titled “Pathways to Freedom, Winning the Fight Against Tobacco” that, under the heading “The Dangers of Menthol” states that “menthol can make it easier for a smoker to inhale deeply, which may allow more chemicals to enter the lungs. Menthol in cigarettes does not make smoking safer. In fact, menthol may even make things worse.” Since we are the leading manufacturer of mentholated cigarettes in the United States, we could face increased exposure to tobacco-related litigation as a result of such allegations. Even if such claims are unsubstantiated, increased concerns about the health impact of mentholated cigarettes could adversely affect our sales, including sales of Newport. Any ban or limitation on the use of menthol in cigarettes would adversely affect our results of operation and financial condition.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

          None.

Item 3. Defaults Upon Senior Securities

          None.

Item 4. Submissions of Matters to a Vote of Security Holders

          None.

Item 5. Other Information

          None.

-28-

Item 6. Exhibits

Exhibit
Number	Description
3.1	Amended and Restated Certificate of Incorporation of Lorillard, Inc., incorporated herein by reference to Exhibit 3.1 to Lorillard’s Current Report on Form 8-K filed on June 12, 2008
3.2	Amended and Restated By-Laws of Lorillard, Inc., incorporated herein by reference to Exhibit 3.2 to Lorillard’s Current Report on Form 8-K filed on June 12, 2008
4.1	Specimen certificate for shares of common stock of Lorillard, Inc., incorporated herein by reference to Exhibit 4.1 to Lorillard, Inc.’s Registration Statement on Form S-4 (File No. 333-149051) filed on May 9, 2008
10.1	Lorillard Tobacco Company Senior Executive Severance Plan, dated as of November 1, 2007*†
10.2	Form of Restricted Stock Award Certificate*†
11.1	Statement regarding computation of earnings per share (see note 7 to the consolidated condensed financial statements).*
31.1	Certification by the Chief Executive Officer of Lorillard, Inc. pursuant to Rule 13a-14(a) or Rule 15d-14(a) *
31.2	Certification by the Chief Financial Officer of Lorillard, Inc. pursuant to Rule 13a-14(a) or Rule 15d-14(a) *
32.1	Certification by the Chief Executive Officer and Chief Financial Officer of Lorillard, Inc. pursuant to 18 U.S.C. Section 1350 (as adopted by Section 906 of the Sarbanes-Oxley Act of 2002) **

*	Filed herewith.
**	Furnished herewith.
†	Management or compensatory plan or arrangement required to be filed pursuant to Item 601(b)(10) of Regulation S-K.

-29-

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 5, 2009

LORILLARD, INC.
By:	/s/ MARTIN L. ORLOWSKY
	Name:	Martin L. Orlowsky
	Title:	Chairman, President and Chief Executive Officer
By:	/s/ DAVID H. TAYLOR
	David H. Taylor
	Director, Executive Vice President Finance and Planning and Chief Financial Officer

EX-10.1

Exhibit 10.1

LORILLARD TOBACCO COMPANY
SENIOR EXECUTIVE SEVERANCE PAY PLAN

Effective as of May 1, 2006,
as amended effective November 1, 2007

Lorillard Tobacco Company (the “Company”) hereby establishes this Senior Executive Severance Pay Plan (the “Plan”) for eligible senior executive employees of the Company (excluding its Chief Executive Officer (the “CEO”)) who terminate employment under the circumstances described below. The Plan is effective as of May 1, 2006, as amended effective November 1, 2007.

The Plan is set forth in the form of the following Questions & Answers. These Questions & Answers address many questions that you may have about the Plan. If you have any questions that are not answered, please contact William Crump at (336) 335-7000.

A. Eligibility Rules

1. What are the eligibility rules?

     In general, you are eligible, and will receive benefits under the Plan, if you:

• Are a senior executive of the Company designated by the CEO as eligible for benefits under this Plan (the list of eligible executives is set forth on Exhibit A, as amended from time to time (but subject to C.3 below) in the sole discretion of the CEO);

• (a) voluntarily Terminate for Good Reason; or (b) are involuntarily Terminated by the Company other than for Cause; and

• Comply with A.2 below, including the signing of the required Release.

     For purposes of the Plan, the following terms have the following meanings:

“Base Salary” means the greater of your actual annual base salary, exclusive of incentive bonuses or any other payments, as of the Effective Date or as of any time after the Effective Date.

“Cause” means Termination by the Company for: (i) any malfeasance in office or other similar violation of your duties and responsibilities; (ii) violation of express instructions or any specific Company policy which materially affects the business of the Company; or (iii) any unlawful act which, in the reasonable judgment of the CEO, harms the reputation of the Company or otherwise causes significant injury to the Company.

“Code” means the Internal Revenue Code of 1986, as amended from time to time, including regulations and guidance issued thereunder. References to any section of the Code shall be to that section as it may be renumbered, amended, supplemented or reenacted.

“Current CEO” means Martin L. Orlowsky.

“Disability” means you are either: (i) entitled to long term disability benefits under the Company’s long-term disability plan or (ii) determined to be totally and permanently disabled by the Social Security Administration.

“Effective Date” means May 1, 2006 with respect to those named on Exhibit A as of that date. If you are added to the list in Exhibit A after that date, the Effective Date is the date the CEO directs your addition to the list on Exhibit A in writing.

“Good Reason” means the occurrence of any of the following:

(1) the assignment to you of any duties inconsistent in any respect with your title, authority, duties or responsibilities as in effect on or after the Effective Date, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of written notice thereof given by you; or

(2) a failure by the Company to comply with any of the following provisions: (a) not to reduce your Base Salary; (b) to amend, modify or terminate this Plan (or Exhibits A and B) in a manner not permitted by C.3; or (c) to permit you to participate in all incentive, bonus, savings and retirement benefit plans, practices, policies and programs applicable generally to other peer executives of the Company. However, an isolated, insubstantial or inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of written notice thereof given by you does not constitute Good Reason under this paragraph (2).

Good Reason does not include your death, your Disability, or your removal from the list of eligible executives set forth in Exhibit A (if so permitted under C.3). Your failure to provide timely notice of any event otherwise constituting Good Reason will permit the Company to effect a cure, if such cure is possible, and will waive your right to assert Good Reason if a cure by the Company would have been possible had notice been given timely, but no longer is possible.

“Separation Date” means the day your employment Terminates, as designated by the Company.

“Severance Amount” means an amount equal to twice your Base Salary on your Separation Date (determined without regard to any decrease giving rise to a Termination for Good Reason). In determining your Base Salary for this purpose, any performance/merit reviews that are pending or in process as of your Separation Date will not be taken into account.

“Termination” and its variants mean a termination of employment with the Company and all its subsidiaries and affiliates that constitutes a “separation from service” under Treasury Regulation Section 1.409A-2(h). The Company and you both agree that it is intended that you will perform no further services for the Company following the effective date of your separation.

2. What must I do to receive severance benefits?

If you are listed in Exhibit A, and if you voluntarily Terminate for Good Reason or if you are involuntarily Terminated other than for Cause, you will receive severance benefits under this Plan provided that you:

• Sign (and not revoke) a release agreement satisfactory to the Company (the “Release”). Such Release will be presented to you at the time you become eligible to receive severance benefits under the Plan and, as of May 1, 2006, is in the form set forth in Exhibit B. Subject to C.3, the Company reserves the right to modify the terms of the form Release set forth in Exhibit B at its discretion;

• Return any financial advances and Company property that you may have by your Separation Date; and

• Reconcile your expense account and repay any Company loans in full by your Separation Date.

3.	Will I receive severance benefits if I voluntarily Terminate other than for Good Reason or if I am Terminated for Cause?
	No. If you voluntarily Terminate your employment other than for Good Reason, or if you are Terminated for Cause, you will not be eligible for severance benefits under this Plan. Your failure to return from a vacation or an approved leave of absence will be considered a voluntary Termination on your part other than for Good Reason.
4.	Are there other situations in which my employment Terminates and I will not receive benefits under this Plan?
	Yes. You will not receive benefits under this Plan if you die while employed or if you Terminate on account of Disability or retirement.

B. Severance Benefits

1. What are the severance benefits if I am Terminated without Cause or if I Terminate for Good Reason?

Subject to B.5 below, if you satisfy the requirements discussed above:

•	The Company will pay you the Severance Amount in equal bi-monthly installments over a period of thirty-six (36) months commencing on the first payroll date after your execution, and acceptance by the Company, of a Release and the expiration of any revocation period set forth in the Release, with subsequent bi-monthly installments paid in accordance with the Company’s regular payroll practice. However, payment of the Severance Amount will cease should you begin to receive retirement benefits under the Company’s pension plan within that 36-month period.
•	You will receive as a severance benefit hereunder, but only to the extent not paid pursuant to the terms of the Lorillard Management Incentive Plan, the Lorillard Executive Incentive Plan or any successors thereto (collectively, the “MIP”), an amount equal to what you would have received under the MIP with respect to the year in which you Terminate had you: (i) remained employed throughout the entire year on the same terms as in effect before the event resulting in your Termination; and (ii) been credited with the full amount of the incentive compensation for which you were eligible under the MIP for that year. Such payments shall be made on the normal payment date(s) under the MIP with respect to that year as if you had not incurred a Separation Date.
	Under the MIP as in effect on May 1, 2006, incentive compensation is determined in December for the year ending in December and deemed earned at that time. One-half of any incentive compensation earned in that year is paid in December of the year earned and the other half is paid in December of the following year, assuming you remain employed by the Company through that following December. Thus, by way of example only, assume that the MIP as in effect on May 1, 2006 continues without amendment and you are Terminated by the Company in July 2006 without Cause. To the extent not paid pursuant to the MIP, you will receive pursuant to this Plan: (i) in December 2006, the remainder of your 2005 incentive compensation earned in December 2005 with interest thereon and one-half of your 2006 incentive compensation (as if you had remained employed throughout 2006 and received the full award for which you were eligible in 2006); and (ii) in December 2007, the remainder of your 2006 incentive compensation earned in December 2006 with interest thereon (as if you had remained employed throughout 2007 and received the full award for which you were eligible in 2006, but with no award for 2007).
•	As long as (i) you are receiving payments of the Severance Amount hereunder and (ii) you have not accepted employment elsewhere which offers health benefits substantially similar to the Company’s health benefits, the Company will pay you a monthly benefits payment (the “Benefits Payment”).

The Benefits Payment will be equal to the total monthly COBRA premium for coverage of you and your COBRA-eligible dependents under the Company’s health plan, as of the date of your Termination, but “grossed-up” for taxes (using an effective tax rate of 35%). The Benefits Payment will be made on the first day of each month, commencing on the first day of the month following your execution and acceptance by the Company, of a Release and the expiration of any revocation period set forth in the Release. However, the Benefits Payment will cease should you begin to receive retirement benefits under the Company’s pension plan or if you begin benefits under the Company’s retiree medical plan.

•

The Company will provide and pay for reasonable outplacement services actually used by you until such time as you accept other employment, but in no event for more than twenty-four (24) months. The Company will work with you to select the outplacement firm.

The Severance Amount and the other benefits provided herein will be in lieu of any other severance benefits provided under any Company plans, practices, policies, programs or agreements, whether now existing or hereafter adopted. Also, the Company will pay you in a lump sum in cash within 30 days after the Separation Date, to the extent not theretofore paid, an amount equal to the sum of: (i) your Base Salary through the Separation Date and (ii) any accrued vacation pay through the Separation Date, both amounts calculated without regard to any decrease giving rise to a Termination for Good Reason. All options held by you under the Loews’ Carolina Group 2002 Stock Option Plan (or successor thereto) will be exercisable in accordance with the terms of that plan, as amended from time to time. See C.2 below as to other Company benefits.

You are not required to mitigate the amount of any payments made under this Plan by seeking other employment.

2. What are the severance benefits if I Terminate due to Disability or Death, or if I die after my Termination?

If you Terminate due to Disability or death, the Plan will not provide any benefits. Instead, you or your dependents will be entitled to any benefits due under the specific terms of any Company plan, practice, policy or program for which you or your dependents, as the case may be, are eligible.

If you voluntarily Terminate for Good Reason or are involuntarily Terminated without Cause and you die after your Release is executed and the revocation period has expired, your estate will be paid the full amount of any unpaid portion of the Severance Amount and the Benefits Payment as soon as practicable, but not later than the 60^th day, following your death. Similarly, if you voluntarily Terminate for Good Reason or are involuntarily Terminated without Cause and you die before your Release is executed or the revocation period has expired, then if your estate executes and does not revoke a Release (or does not revoke the Release you executed, as the case may be), your estate will be paid the full amount of the Severance Amount and the Benefits Payment as soon as practicable, but not later than the 60^th day, following your death. In either case, your estate will be paid the severance benefit in lieu of the MIP, as described in B.1 above, in the first December following your death.

3. When will I receive my severance benefits?

Severance generally will begin to be paid to you following the expiration of the revocation period, if any, set forth in the Release; e.g., the Release may provide for a 7-day revocation period. You will not be paid severance until after the revocation period has expired and the Release becomes effective and enforceable. Please note that you cannot sign your Release prior to your Separation Date.

However, If you are a “specified employee,” as defined under Code Section 409A, at the time of your Termination, then to the extent required under Code Section 409A the benefits to which you would

otherwise be entitled in the first six months following your Separation Date will be accumulated, will accrue interest at the rate provided in Code Section 1274(b)(2)(B) and will be paid as of the first payroll date in the seventh month following your Separation Date.

4. What about my Indemnification and D&O Insurance?

You will be entitled to indemnification for acts through the Separation Date under the terms of the Company’s Certificate of Incorporation as in effect on the Separation Date, regardless of later amendments to such Certificate of Incorporation (other than amendments required by applicable law), unless the indemnification provided under such amendments is more favorable to you. Also, the Company will maintain on your behalf liability insurance coverage (commonly known as “D&O coverage”) comparable to that in effect as of the Separation Date, covering acts through the Separation Date.

5. Are there any limitations on my Severance Benefits?

Yes, there may be a limitation if your Termination occurs in connection with a “change in control” of the Company, as defined under Code Section 280G. In case of such a “change in control,” on advice of its independent public accountants or of its counsel, the Company may determine that part or all of the benefits to be paid to you pursuant to this Plan, together with other amounts of compensation due from the Company, constitute “parachute payments” as defined under Code Section 280G(b)(2) (collectively, the “Parachute Amount”). In that event, if: (i) the benefits under this Plan are considered to be subject to Code Section 280G(b)(2) and (ii) the Parachute Amount exceeds 2.99 times your “base amount,” as defined in Code Section 280G(b)(3) (the “Base Amount”); then your benefits under this Plan: (x) will be reduced, to the extent necessary, so that your Parachute Amount is equal to 2.99 times your Base Amount; or (y) will not be paid at all if, even after total elimination of your Plan benefits, your Parachute Amount equals or exceeds 3.00 times your Base Amount.

If Plan benefits are reduced as provided above, the Company will first reduce or eliminate the Severance Amount, next reduce or eliminate the MIP replacement payments, and last reduce or eliminate other entitlements under the Plan. To the extent not reduced or eliminated, benefits will continue as provided under the Plan.

C. Other Questions

1. When must I sign the Release?

You will be given a period of time, which will be specified in the Release, to consider whether to sign the Release and you will have a revocation period thereafter, typically 7 days, in which you may revoke the Release for any reason. In no event may you sign the Release before your Separation Date.

2. How are my other Company benefits impacted by my Termination?

Other than the severance benefits under this Plan described above, upon your Termination, all your other benefits will end in accordance with the terms of the applicable benefit plans and documents and as otherwise required by applicable law. Further, if you are Terminated without Cause or Terminate for Good Reason, you will not be eligible for benefits under any other severance pay plan, program or policy, whether oral or written, previously adopted or applied by the Company.

3. Can the Company change the Plan?

At any time before the Current CEO ceases to serve as CEO or after the third anniversary of the date the

Current CEO ceases to act as CEO, the Company (or a CEO with respect to any authority delegated to a CEO) reserves the right to amend, modify or terminate this Plan at any time and in any manner, in whole or in part, without advance notice to you. Notwithstanding anything to the contrary in the preceding sentence, no amendment, modification or termination of the Plan adopted after your Separation Date will affect your Plan benefits without your consent. During the three year period after the Current CEO ceases to serve as CEO, (i) the Company may not amend, modify or terminate the Plan, Exhibit A (except by action of the CEO to add executives thereto, but with no authority of the Company or the CEO to delete executives therefrom) or Exhibit B except as required to conform with applicable law or to avoid adverse tax consequences due to a change in applicable law, and (ii) any action contravening the preceding clause (i) shall not be effective for any purpose under the Plan. Further, any right to amend, modify or terminate the Plan will not include any right to amend, modify or terminate the Plan in a manner that does not comply with Code Section 409A or other applicable law.

D. Administration

1. Who administers the Plan?

The Plan Administrator is the Company, through its Board of Directors (the “Board”). The Plan Administrator may delegate to any one or more of the Company’s employees any responsibility it may have under the Plan. The Plan Administrator, or its delegate, makes the rules and regulations necessary to administer the Plan and has the discretionary authority and responsibility to construe the terms of the Plan and to make any factual determinations under the Plan, as well as the administrative authority to determine the amount of payments and, with respect to welfare benefits, in what form such benefits will be provided. The determinations and constructions of the Plan Administrator, or its delegate, will be final, binding and conclusive as to all parties, unless found by a court of competent jurisdiction to be arbitrary and capricious. Until another designation is made by the Board, the Vice President of Human Resources is delegated the responsibility for the day-to-day administration of the Plan on behalf of the Company.

2. If I disagree with any determination made under this Plan, including my eligibility for severance benefits or the amount of my severance benefits, who should I contact?

If you are eligible for severance benefits under this Plan, you will be notified and provided with a Release and any other forms required in connection with receipt of severance benefits.

If you disagree with a determination of your eligibility for, or as to the amount of, severance benefits under this Plan you may, within 30 days of (1) receipt of the Release, or (2) the event which you feel should have led to your eligibility for benefits under this Plan, submit a written statement to the Plan Administrator describing the basis of your claim for severance benefits, together with any documents you believe support your claim.

If any claim for severance benefits cannot be decided due to lack of sufficient information, you will be notified and given time to provide additional information to support your claim. If your claim for severance benefits is wholly or partially denied, the Plan Administrator, or its delegate, will notify you within 90 days after your claim is submitted. In special circumstances the Plan Administrator, or its delegate, may take up to an additional 90 days to consider the decision, in which case you will be notified of the extension.

Any denial of a claim will be in writing and will include: (1) the reasons for the denial (including reference to any pertinent Plan provisions on which the denial is based); (2) if applicable, a description of any additional material or information necessary for you to complete the claim, and an explanation of why such material or information is necessary; and (3) a description of the claims review procedure,

including a statement of your right to bring a civil action under ERISA following an adverse determination on appeal.

If your claim is denied, you may make a written request to the Board, within 60 days after such denial, for a review of the denial. Any such request may include a request for pertinent documents. You will be notified of the final decision of the Board within 60 days after your request for review is received. In special circumstances the Board may take up to an additional 60 days to consider its decision, in which case you will be notified of the extension. If your claim is denied upon review, the decision will be in writing and will: (1) set forth the specific reasons for the denial (including reference to any pertinent Plan provisions on which the denial is based); (2) include a statement that you are entitled to receive, upon request and free of charge, reasonable access to and copies of all documents, records and other information relevant to your claim for benefits; and (3) include a statement of your right to bring a civil action under ERISA.

The Board’s, or its delegate’s, decision on claims will be final, binding and conclusive on all interested persons unless found by a court of competent jurisdiction to be arbitrary and capricious.

E. General Information about the Plan.

Books and Records

The Plan Administrator and others to whom duties are delegated pursuant to the Plan will keep a record of all their proceedings and actions and will maintain all such books of account, records and other data as necessary for the proper administration of the Plan.

Plan Year

The Plan’s records are kept on a calendar year basis.

Limits of Liability; Indemnification

No person participating in any determination of any question under the Plan, or in the interpretation, administration or application of the Plan, will have any liability to any person for any action or omission to act taken or omitted in good faith under the Plan. The Company will indemnify and hold harmless any such person against any and all claims, losses, damages, expenses or liabilities arising from any action or inaction with respect to this Plan, except in the case of such person’s willful misconduct.

Nonassignability

Except as may otherwise be required by law, neither you nor any other person has any right to commute, sell, assign, transfer, pledge, anticipate, mortgage or otherwise encumber, transfer, hypothecate, alienate or convey in advance of actual receipt, the amounts, if any, payable hereunder, or any part thereof, which are, and all rights to which are expressly declared to be, nonassignable and non-transferable. No part of the amounts payable will, prior to actual payment, be subject to seizure, attachment, garnishment or sequestration for the payment of any debts, judgments, alimony or separate maintenance owed by you or any other person, be transferable by operation of law in the event of your or any other person’s bankruptcy or insolvency or be transferable to a spouse as a result of a property settlement or otherwise.

Notwithstanding the preceding paragraph, if you are indebted to the Company or any affiliate of the Company any time when a payment is to be made to you under the provisions of the Plan, the amount of the payment to be made to you may be reduced, as

determined by the Plan Administrator, to the extent of such indebtedness. Any election not to reduce such payment will not constitute a waiver of the claim for such indebtedness.

Unfunded Plan

You have no rights under the Plan other than as an unsecured general creditor of the Company. Nothing in this Plan requires the Company to purchase assets or place assets in a trust or other entity or otherwise to segregate any assets for the purpose of satisfying any obligations under the Plan, and you will have no secured interest in or claim on any assets of the Company. The Company nevertheless may place assets in a trust pursuant to one or more trust agreements between the Company and a trustee. The assets of any such trust are subject to the Company’s general creditors, and you will have no secured interest in or claim on any such assets.

No Right of Employment

Nothing in this Plan will be construed as creating any contract of employment or conferring upon you any right to continue in the employ or other service of the Company or limit in any way the right of the Company to Terminate your employment with or without Cause.

Section Headings

The section headings and captions contained herein are for convenience only, and in the event of any conflict, the text of the Plan, rather than the section headings and captions, will control.

Invalidity of Provisions

The invalidity and unenforceability of any particular provision of this Plan will not affect any other provision and the Plan will be construed in all respects as if such invalid or unenforceable provisions were omitted.

Taxes and Withholding

All severance payments and benefits under this Plan will be subject to the withholding of any employment or other taxes that the Company is required to withhold under federal, state or local law.

This Plan is intended to comply with Section 409A of the Code, which governs deferred compensation and severance pay plans; and the Plan will be interpreted, operated and administered accordingly. Notwithstanding the foregoing, the Company does not guarantee the tax treatment of any payment or benefits under this Plan, including without limitation under the Code, federal, state and local laws.

Governing Law

The Plan will be governed by the laws of the State of North Carolina, as determined without regard to the conflict of law principles thereof, except to the extent such laws are preempted by ERISA. For purposes of ERISA, this Plan is intended to constitute a nonqualified, unfunded plan for the purpose of providing deferred compensation for a select group of management or highly compensated employees. This Plan is intended to be interpreted in a manner that conforms to the requirements of Code Section 409A.

EX-10.2

Exhibit 10.2

FORM OF LORILLARD, INC.
RESTRICTED STOCK
AWARD CERTIFICATE

          THIS CERTIFICATE, dated as of the ___day of                     , evidences the grant of the Award set forth below by Lorillard, Inc., a Delaware corporation (the “Company”) to                      (the “Participant”).

RECITALS

          The Compensation Committee (the “Committee”) of the Board of Directors of the Company has determined to grant to the Participant restricted shares of the Company’s common stock, par value $0.01 per share, (the “Company Stock”) pursuant to the Lorillard, Inc. 2008 Incentive Compensation Plan (the “Plan”), on the terms and conditions set forth herein, and hereby grants such restricted shares.

          Any capitalized terms not defined herein shall have their respective meanings as set forth in the Plan.

          NOW, THEREFORE, the Parties hereto agree as follows:

     1. Grant of Restricted Stock. Subject to the provisions of this Certificate and the Plan, the Company hereby grants to the Participant as of ___(the “Date of Grant”) ___shares of Company Stock (the “Award”) pursuant to the terms and conditions of this Certificate (the “Restricted Stock”), subject to the restrictions set forth below and the terms of this Agreement. The Participant shall not be required to pay any cash consideration in exchange for the Restricted Shares.

     2. Restrictions and Restricted Period.

          (a) Restrictions. Shares of Restricted Stock granted hereunder may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of and shall be subject to a risk of forfeiture as described in Section 4 below until the lapse of the Restricted Period (as defined below).

          (b) Restricted Period. The restrictions set forth above shall lapse and the shares of Restricted Stock shall become vested and transferable (provided, that such transfer is otherwise in accordance with federal and state securities laws) on the ___anniversary of the Date of Grant (the period from the Date of Grant until the date on which the restrictions lapse is the “Restricted Period”).

     3. Rights of a Stockholder. From and after the Date of Grant and for so long as the Restricted Stock is held by or for the benefit of the Participant, the Participant shall have all the rights of a stockholder of the Company with respect to the Restricted Stock, including, but not limited to, the right to receive dividends and the right to vote such shares. If there is any stock dividend, stock split or other change in character or amount of the Restricted Stock, then in such event, any and all new, substituted or additional securities to which Participant is entitled by reason of the Restricted Stock shall be immediately subject to the restrictions and risk of forfeiture set forth in Sections 2 and 4 with the same force and effect as the Restricted Stock subject to such restrictions and risk of forfeiture immediately before such event.

     4. Cessation of Service.

          (a) Forfeiture. If the Participant terminates employment for any reason other than those set forth in Section 4(b) of this Agreement or in connection with a Change in Control, then the Restricted Stock for which the Restricted Period has not lapsed shall be forfeited to the Company without payment of any consideration by the Company, and neither the Participant nor any of his successors, heirs, assigns, or personal representatives shall thereafter have any further rights or interests in such shares of Restricted Stock.

          (b) Accelerated Vesting. If prior to the end of the Restricted Period, the Participant terminates employment because of the Participant’s death or Disability, the Restricted Stock will immediately vest in full and the Company shall deliver a certificate or certificates representing the unrestricted shares promptly following such termination of service.

     5. Effect of Change in Control. In the event of a Change of Control (as defined in the Plan), the Award if not previously exercisable and vested shall become fully exercisable and vested.

     6. Certificates. Restricted Stock granted herein may be evidenced in such manner as the Committee shall determine. If certificates representing Restricted Stock are registered in the name of the Participant, then the Company may retain physical possession of the certificate until the Restricted Period has lapsed.

     7. Legends. The Company may require, as a condition of the issuance and delivery of certificates evidencing Restricted Stock pursuant to the terms hereof, that the certificates bear the legend as set forth immediately below, in addition to any other legends required under federal and state securities laws or as otherwise determined by the Committee. All certificates representing any of the shares of Restricted Stock subject to the provisions of this Agreement shall have endorsed thereon the following legend:

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS UPON TRANSFER HELD BY THE ISSUER OR ITS ASSIGNEES(S) AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE HOLDER OF THE SHARES, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.

     Such legend shall not be removed until such shares vest pursuant to the terms hereof.

     8. Taxes. The Participant understands that he (and not the Company) shall be responsible for any tax liability that may arise as a result of the transactions contemplated by this Agreement.

     9. Nontransferability of the Award.

          The Award is not transferable except (i) as designated by the Participant by will or by the laws of descent and distribution or (ii) as otherwise expressly permitted by the Committee including, if so permitted, pursuant to a transfer to such Participant’s immediate family, whether directly or indirectly or by means of a trust or partnership or otherwise. If any rights exercisable by the Participant or benefits deliverable to the Participant under this Certificate have not been exercised or delivered at the time of the Participant’s death, such rights shall be exercisable by the Designated Beneficiary, and such benefits shall be delivered to the Designated Beneficiary, in accordance with the provisions of this Certificate and the Plan.

     10. Notices.

          All notices and other communications under this Certificate shall be in writing and shall be given by hand delivery to the other party or by confirmed fax or overnight courier, or by postage paid first class mail, addressed as follows:

          If to the Participant:

          If to the Company:

Lorillard, Inc.
714 Green Valley Road
Greensboro, NC 27408
Attention: Corporate Secretary
Facsimile: (336) 335-7707

or to such other address or facsimile number as any party shall have furnished to the other in writing in accordance with this Paragraph 10. Notice and communications shall be effective when actually received by the addressee.

     11. Effect of Certificate.

          Except as otherwise provided hereunder, this Certificate shall be binding upon and shall inure to the benefit of any successor or successors of the Company, and to any transferee or successor of the Participant pursuant to Paragraph 9.

     12. Conflicts and Interpretation.

          The Award is subject to the provisions of the Plan, which are hereby incorporated by reference. In the event of any conflict between this Certificate and the Plan, the Plan shall control. In the event of any ambiguity in this Certificate, any term which is not defined in this Certificate, or any matters as to which this Certificate is silent, the Plan shall govern including, without limitation, the provisions thereof pursuant to which the Committee has the power, among others, to (i) interpret the Plan, (ii) prescribe, amend and rescind rules and regulations relating to the Plan and (iii) make all other determinations deemed necessary or advisable for the administration of the Plan.

     13. Headings.

          The headings of paragraphs herein are included solely for convenience of reference and shall not affect the meaning or interpretation of any of the provisions of this Certificate.

     14. Amendment.

          This Certificate may not be modified, amended or waived except by an instrument in writing signed by the Company. The waiver by either party of compliance with any provision of this Certificate shall not operate or be construed as a waiver of any other provision of this Certificate, or of any subsequent breach by such party of a provision of this Certificate.

          IN WITNESS WHEREOF, as of the date first above written, the Company has caused this Certificate to be executed on its behalf by a duly authorized officer.

	LORILLARD, INC.
By:

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Martin L. Orlowsky, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2009 of Lorillard, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2009 By: /s/ Martin L. Orlowsky   Martin L. Orlowsky
Chairman, President and Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATIONS

     I, David H. Taylor, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2009 of Lorillard, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2009

By:	/s/ David H. Taylor
	David H. Taylor
	Director, Executive Vice President, Finance and Planning and Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL
OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Quarterly Report on Form 10-Q of Lorillard, Inc. (the “Company”) for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Martin L. Orlowsky, as Chief Executive Officer of the Company, and David H. Taylor, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Martin L. Orlowsky Name: Martin L. Orlowsky

Title: Chairman, President and Chief

          Executive Officer (Principal Executive Officer)

Date: May 5, 2009

/s/ David H. Taylor Name: David H. Taylor

Title: Director and Executive Vice President,

          Finance and Planning and Chief Financial Officer

          (Principal Financial Officer)

Date: May 5, 2009

This certification shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be incorporated by reference into any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Lorillard, Inc. and will be retained by Lorillard, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.